

## Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)

Ganesha Rai,<sup>\*,†,∞</sup> Kyle R. Brimacombe,<sup>†,∞</sup> Bryan T. Mott,<sup>†</sup> Daniel J. Urban,<sup>†</sup> Xin Hu,<sup>†</sup> Shyh-Ming Yang,<sup>†</sup> Tobie D. Lee,<sup>†</sup> Dorian M. Cheff,<sup>†</sup> Jennifer Kouznetsova,<sup>†</sup> Gloria A. Benavides,<sup>‡</sup> Katie Pohida,<sup>†</sup> Eric J. Kuenstner,<sup>†,◆</sup> Diane K. Luci,<sup>†</sup> Christine M. Lukacs,<sup>§,¶</sup> Douglas R. Davies,<sup>§</sup> David M. Dranow,<sup>§</sup> Hu Zhu,<sup>†</sup> Gary Sulikowski,<sup>⊥</sup> William J. Moore,<sup>#</sup> Gordon M. Stott,<sup>#</sup> Andrew J. Flint,<sup>#</sup> Matthew D. Hall,<sup>†,○</sup> Victor M. Darley-Usmar,<sup>†</sup> Leonard M. Neckers,<sup>||</sup> Chi V. Dang,<sup>▽</sup> Alex G. Waterson,<sup>⊥</sup> Anton Simeonov,<sup>†</sup> Ajit Jadhav,<sup>†</sup> and David J. Maloney<sup>\*,†,○,id</sup>

<sup>†</sup>National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States

<sup>‡</sup>Mitochondrial Medicine Laboratory, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States

<sup>§</sup>Beryllium Discovery Corp., 7869 Day Road West, Bainbridge Island, Washington 98110, United States

<sup>#</sup>Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20892, United States


<sup>⊥</sup>Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States

<sup>||</sup>NEXT Program Support, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States

<sup>▽</sup>Abramson Cancer Center, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

### Supporting Information

**ABSTRACT:** We report the discovery and medicinal chemistry optimization of a novel series of pyrazole-based inhibitors of human lactate dehydrogenase (LDH). Utilization of a quantitative high-throughput screening paradigm facilitated hit identification, while structure-based design and multiparameter optimization enabled the development of compounds with potent enzymatic and cell-based inhibition of LDH enzymatic activity. Lead compounds such as **63** exhibit low nM inhibition of both LDHA and LDHB, submicromolar inhibition of lactate production, and inhibition of glycolysis in MiaPaCa2 pancreatic cancer and A673 sarcoma cells. Moreover, robust target engagement of LDHA by lead compounds was demonstrated using the cellular thermal shift assay (CETSA), and drug–target residence time was determined via SPR. Analysis of these data suggests that drug–target residence time (off-rate) may be an important attribute to consider for obtaining potent cell-based inhibition of this cancer metabolism target.



## INTRODUCTION

Tumor cells are often dependent on glycolysis for adenosine 5'-triphosphate (ATP) biosynthesis, even in the presence of sufficient oxygen to support oxidative phosphorylation, a process termed aerobic glycolysis and classically known as the “Warburg effect”.<sup>1</sup> In such cancers, tumor cells exhibit a high rate of glycolysis, metabolizing glucose into pyruvate, which instead of entering mitochondria is reduced by lactate dehydrogenase (LDH) to lactate and excreted by the cells. This is in stark contrast to classic aerobic metabolism, in which cells demonstrate low rates of glycolysis and instead rely on the

oxidation of pyruvate in mitochondria for a comparatively greater energy payoff. Though aerobic glycolysis is an inefficient way to generate ATP, it has been proposed that rapidly proliferating cancer cells have adapted this approach to facilitate the production of essential building blocks like nutrients such as amino acids, lipids, and nucleotides to support rapid cell growth rather than efficient ATP production.<sup>2</sup> LDH is a key glycolytic enzyme that catalyzes the final step in the glycolytic pathway,

Received: July 5, 2017

Published: November 9, 2017





Figure 1. Representative previously described LDH inhibitors and qHTS “hit” 5.

Scheme 1. Syntheses of Analogs 5, 9, and 12–15<sup>a</sup>




<sup>a</sup>Reagents and conditions: (a)  $\text{NH}_2\text{CSNHNH}_2$ , EtOH, reflux, 12 h, 24–35%; (b) (i)  $\text{BrCH}_2\text{COCO}_2\text{Et}$ , EtOH, reflux, 1 h; (ii)  $\text{EtOH}, \text{H}_2\text{SO}_4$ , reflux, 12 h, 55–75%; (c) (i) reversed-phase chromatography separation of regioisomers; (ii)  $\text{HCl}, \text{AcOH}$ , 120 °C, 1 h.


reducing pyruvate to lactate and regenerating  $\text{NAD}^+$  equivalents necessary for continued glycolysis. Expression of the LDHA gene is upregulated in many cancers to support the high glycolytic activity in these cells.<sup>3,4</sup> The LDH enzyme is a tetramer composed of M subunits encoded by the LDHA gene or H subunits encoded by the LDHB gene. In cancer cells, the enzyme composed of 4 M subunits known as LDH-5 is thought to predominate. Throughout this manuscript we will refer to the enzyme as LDHA. Reduction of LDH activity through knockdown or silencing of the LDHA gene has been shown to reduce tumor cell growth *in vitro* under hypoxic conditions and to suppress growth in tumor xenograft models.<sup>5</sup> In addition, high levels of LDHA expression have been correlated with poor clinical outcome for a number of cancer types.<sup>6</sup> Among cancers with unmet therapeutic need, glioblastoma,<sup>7</sup> pancreatic,<sup>8</sup> and advanced stage and rare hereditary kidney cancers<sup>9</sup> are all

highly glycolytic and thus represent potential opportunities for LDH inhibitors to provide clinical benefit.

However, despite its promise, LDHA has proven to be a relatively intractable drug target. The enzyme active-site has a highly mobile loop that caps the binding site for the small polar organic anion substrate (pyruvate or lactate) and an extended solvent exposed channel that binds cofactor. These features, combined with the high protein levels of LDH in cancer cells, necessitate a small molecule inhibitor that binds with remarkable efficiency while simultaneously maintaining druglike properties. Initial disclosures of LDH inhibitors emerged out of academic laboratories (e.g., FX-11<sup>5b</sup> and NHI-2<sup>10</sup>) with efforts from biotech<sup>11</sup> and pharmaceutical companies, such as AstraZeneca (e.g., 1),<sup>12</sup> emerging later. To date, no clinical-stage inhibitors of LDH have been reported; molecules from GlaxoSmithKline (GSK) (2)<sup>13</sup> and Genentech (3)<sup>14</sup> have shown modest cellular potency *in vitro* (e.g., inhibition of

**Scheme 2. Syntheses of Precursors I, II, and III and Analogs 7 and 10<sup>a</sup>**

<sup>a</sup>Reagents and conditions: (a)  $\text{BF}_3\cdot\text{OEt}_2$ ,  $\text{CH}_2\text{Cl}_2$ –THF, 12 h, 88%; (b)  $\text{N}_2\text{H}_4$ , EtOH, reflux, 2 h, 82%; (c) EtOH, reflux, 5 h; (d) EtOH, AcOH, reflux, 12 h, 77%; (e) TFA,  $\text{CH}_2\text{Cl}_2$ ; (f)  $\text{Ac}_2\text{O}$ , pyridine, 100 °C.

**Scheme 3. Synthesis of 11, 16–32, and 33–41<sup>a</sup>**

<sup>a</sup>Reagents and conditions: (a)  $\text{CH}_3\text{CO}_2\text{Et}$ , LDA, THF,  $-78$  °C, 2–6 h, 15–90%; (b) II, AcOH, EtOH, reflux, 12 h, 12–70%; (c) TFA,  $\text{CH}_2\text{Cl}_2$ , 1 h; (d)  $\text{NaH}$ , dioxane, 1 h, 0 °C, 60–75%; (e) III, EtOH,  $\text{TsOH}$ , MW, 15 min, 46–86%; (f)  $\text{LiOH}$ , THF/MeOH/ $\text{H}_2\text{O}$ , 1 h. <sup>b</sup>Commercially available.


lactate production) but no appreciable *in vivo* activity and do not appear to have progressed into clinical studies.

We designed and performed a quantitative high-throughput screening (qHTS) campaign, and utilized structure-based design and hit-to-lead optimization to discover novel compounds that are potent inhibitors of LDH enzyme activity, cellular lactate output, and cancer cell line growth. Lead compounds from our work exhibit low nM inhibition of LDHA/LDHB and sub- $\mu\text{M}$  inhibition of lactate production in MiaPaCa2 and A673 cells. Further, robust target engagement of LDHA with these lead compounds was demonstrated by cellular thermal shift assay (CETSA), and drug–target residence time was determined via SPR. Among these parameters, drug–target residence time (off-rate) appears to

be a particularly strong predictor of cell-based inhibition of the target. In this report, we describe the discovery and medicinal chemistry optimization of a novel series of pyrazole-based LDH inhibitors. Compound 63 has proven to be a promising lead compound worthy of further optimization, given its sub- $\mu\text{M}$  inhibition of cellular lactate production, demonstrated cellular target engagement, slow *in vitro* off-rate, good microsomal stability and aqueous solubility.

## ■ CHEMISTRY

The qHTS identified trifluoromethylpyrazole compound 5 as a hit candidate that was evaluated via extensive SAR studies. Initial medicinal chemistry efforts focused on the pyrazole substituents. The syntheses of 5 and related analogs 9, 12–15

Scheme 4. Synthesis of 43–45<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) ethyl 2-bromothiazole-4-carboxylate, K<sub>2</sub>CO<sub>3</sub>, 120 °C, 3–4 h, 27–78%; (b) bis(pinacolato)diboron, PdCl<sub>2</sub>(dpdpf), AcOK, 1,4-dioxane, 95 °C, overnight 49%; (c) 4-(bromomethyl)benzenesulfonamide, 2N Na<sub>2</sub>CO<sub>3</sub> (aq), Pd(Ph<sub>3</sub>P)<sub>4</sub>, toluene/EtOH (3/1), 80 °C, 2 h, 64–95%; (d) 1.5N LiOH (aq), THF, 2 h; (e) 4-hydroxybenzenesulfonamide, K<sub>2</sub>CO<sub>3</sub>, acetone, 20 h, 92%; (f) 1,1-dimethoxy-N,N-dimethylmethanamine, 90 °C, overnight, then N<sub>2</sub>H<sub>4</sub>, EtOH, 60 °C, 4 h, 27%.


were accomplished following slight modifications to a known literature method.<sup>15</sup> As outlined in Scheme 1, commercially available trifluoromethyl- $\beta$ -diketones were condensed with thiosemicarbazide to obtain key intermediates 5b, 9b, 12b–15b and 5c, 9c, 12c–15c as a mixture of regioisomers, as reported previously.<sup>15</sup> The unseparated mixture of the regioisomers was condensed with ethyl 3-bromo-2-oxopropionate in the presence of sulfuric acid to obtain a ~50/50 mixture of regioisomers 5d, 9d, 12d–15d and 5e, 9e, 12e–15e, which were separated using reversed-phase chromatography. The regioisomers were distinguished by their differences in carbon and fluorine NMR as reported for similar compounds in the literature<sup>16</sup> and via LC/MS co-injection with a reference compound obtained from commercial source. The desired 3-aryl-substituted regioisomer is slightly less polar in nature and elutes as a second peak in reversed-phase HPLC. The resulting product was subsequently hydrolyzed with concentrated hydrochloric acid to obtain analogs 5, 9, and 12–15.

The synthesis of the key precursors I, II, and III along with analogs 7 and 10 is outlined in Scheme 2. Key intermediate *tert*-butyl 2-hydrazinylthiazole-4-carboxylate (II) was synthesized by esterification of the requisite 2-bromothiazole-4-carboxylic acid (Ia) to form the *tert*-butyl ester (I). Subsequent displacement of the bromide with hydrazine at reflux provided II in 82% yield. Condensation of the acetylthiosemicarbazide (IIIa) with ethyl bromopyruvate (IIIb) in ethanol initially forms an acetyl derivative of ethyl 2-hydrazinylthiazole-4-carboxylate that is eventually cleaved in situ by the hydrogen bromide generated during the reaction to form ethyl 2-hydrazinylthiazole-4-carboxylate (III) as a HBr salt. Subsequent acid catalyzed reaction of II with benzoylacetone in ethanol followed by deprotection of the *tert*-butyl ester group gave 7, or acetylation of the formed aminopyrazole intermediate followed by *tert*-butyl deprotection provided 10 as shown in Scheme 2.


The synthetic route for hydroxypyrazole analogs 11 and 16–41 listed in Tables 1 and 2 is described in Scheme 3.

Accordingly, direct condensation of the  $\beta$ -keto esters (11b, 16b–32b) in the presence of acetic acid with II and subsequent cleavage of the *tert*-butyl ester group with TFA afforded analogs 11 and 16–32. For the synthesis of analogs 33–41, the  $\beta$ -keto esters (11b, 27b, 31b, 32b and 36a) were alkylated with appropriately substituted benzyl bromides (33a–35a and 39a–41a) in the presence of sodium hydride in dioxane. The alkylated  $\beta$ -keto esters (33b–41b) are then heated with III under microwave irradiation in the presence of catalytic amount of tosic acid to obtain the cyclized esters. Interestingly, cyclization catalyzed by acetic acid in this case mostly produced a major unidentified byproduct. However, switching to tosic acid exclusively formed the desired 5-hydroxypyrazole derivative. Finally, analogs 33–41 were obtained by the LiOH hydrolysis of the corresponding ethyl esters in THF-methanol–water solvent. Commercially unavailable  $\beta$ -keto esters (21b and 27b–32b) and 4-(bromomethyl)benzenesulfonamide (33a) were prepared according to the literature method.<sup>17</sup>

Scheme 4 illustrates a general strategy for the synthesis of analogs 43–45. Potassium carbonate-catalyzed reaction of ethyl 2-bromothiazole-4-carboxylate with the requisite commercially available bromopyrazole derivatives (43a and 44a) in DMSO at 120 °C gave intermediates 43b and 44b. The formed thiazole-containing intermediates 43b and 44b were then converted to corresponding boronic acid pinacol esters 43c and 44c by PdCl<sub>2</sub>(dpdpf) catalyzed cross coupling with bis (pinacolato)-diboron using potassium acetate as base at 80 °C. Suzuki coupling of 43c and 44c with 4-(bromomethyl)benzenesulfonamide (33a), following a standard protocol catalyzed by tetrakis(triphenylphosphine)palladium(0) in the presence of aqueous sodium carbonate base and subsequent ester hydrolysis using LiOH, provided analogs 43 and 44. Preparation of analog 45 commenced with potassium carbonate-assisted alkylation of commercially available phenacyl bromide (45a) with 4-hydroxybenzenesulfonamide to provide 45b in 92% yield. Intermediate 45b was dissolved in a solution

Scheme 5. Synthesis of 46 and 47<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) *i*-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 1 h, 96%; (b) Fe, NH<sub>4</sub>Cl, EtOH, reflux, 94%; (c) *t*-BuBrettPhos, *t*-BuBrettPhos-palladacycle, LiHMDS, THF, 80 °C, 14 h, 62–83%; (d) K<sub>2</sub>CO<sub>3</sub>, 125 °C, 14 h, 60%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 100 °C, MW, 15 min.

Scheme 6. Synthesis of 48–50<sup>a</sup>


<sup>a</sup>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMSO, 120 °C, 24 h, 25%; (b) HATU, *i*-Pr<sub>2</sub>NEt, DMF, 60 °C, 4 h; (c) NaBH<sub>3</sub>CN, AcOH, MeOH; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 1 h; (e) K<sub>2</sub>CO<sub>3</sub>, DMSO, 125 °C, 3 h, 52%.

of DMF–DMA and heated to form the formyl derivative in situ which was then refluxed with hydrazine in ethanol to give pyrazole derivative **45c** in 27% yield. Finally, coupling of **45c** with ethyl 2-bromothiazole-4-carboxylate using potassium carbonate in DMSO was followed by LiOH hydrolysis of the ester to provide analog **45**.

Access to analogs **46** and **47** was achieved using the synthetic route outlined in Scheme 5. The key precursor, 4-aminobenzenesulfonamide derivative **IVd**, was prepared starting from *p*-nitrobenzenesulfonyl chloride (**IVb**) by protecting the sulfonyl group with bis(3,4-dimethoxybenzyl)-amine (**IVa**), followed by nitro reduction using iron/ammonium chloride in ethanol. Subsequent Buchwald amination of **IVd** was carried out with 4-bromo-3-arylpyrazole (**43a** and **44a**) using *t*-BuBrettPhos and *t*-BuBrettPhos palladacycle catalyst system with LiHMDS in THF to furnish the intermediates **46a** and **47a** in good yield. The choice of LiHMDS as the base and protection of the sulfonamide were

critical for the success of the amination reaction. Several attempts to couple the amine with the unprotected sulfonamide were unsuccessful. Finally, potassium carbonate assisted coupling of **46a** and **47a** with **I** in DMSO at 125 °C followed by deprotection of the *tert*-butyl ester afforded analogs **46** and **47**.

A common synthetic strategy was used to synthesize analogs **48–50**. As depicted in Scheme 6, potassium carbonate-assisted S<sub>N</sub>Ar bromide displacement on **I** with 3-phenyl-1*H*-pyrazol-4-amine (**Va**) or 3-phenyl-1*H*-pyrazole-4-carbaldehyde (**49a**) in DMSO at elevated temperatures gave intermediates **V** and **49b**, respectively. Notably, the S<sub>N</sub>Ar reaction of **I** with any 3,4-disubstituted pyrazoles was accomplished using the combination of potassium carbonate base, DMSO as a solvent, and an optimal temperature between 120 and 130 °C depending on the type of the substitution at 4-position of the pyrazole. As exemplified for intermediate **V**, the reaction proceeds at 120 °C to give the desired product in low yield. However, the product

Scheme 7. Synthesis of 51–57<sup>a</sup>


<sup>a</sup>Reagents and conditions: (a) MeCN, LDA, −78 °C, 4 h, 78–97%; (b) Hantzsch ester, L-Pro, EtOH, 60 °C, 0.5 h, 86–98%; (c) III, TsOH, EtOH, 150 °C, MW, 15 min, 60–77%; (d) TsOH, NaNO<sub>2</sub>, KI, MeCN, 12 h, 36–47%. (e) 52: CuCN, DMSO, 160 °C, 0.5 h, 78%. (f) 51, 53–55: requisite boronic acid, SiliCat-DPP-Pd, Na<sub>2</sub>CO<sub>3</sub>, DME, MW, 130 °C, 0.5 h. (g) 57: (1,10-phenanthroline)(trifluoromethyl)copper(I), DMF, 55 °C, 1 h, 97%; (i) LiOH, THF–MeOH, 1 h.

completely decomposes at higher temperatures, yet the reaction is sluggish at lower temperatures or using alternative conditions. Intermediates V and 49b were then subjected to amine coupling with either 4-sulfamoylbenzoic acid (48a) using HATU or reductive amination with 4-formylbenzenesulfonamide (50a) or 1-piperazinesulfonamide (VI) using sodium cyanoborohydride followed by TFA deprotection of the *tert*-butyl ester group to obtain analogs 48–50.

The syntheses of analogs 51–57 required an alternative and novel synthetic strategy, as our initial attempts to access these analogs from hydroxypyrazoles or alkylation of trifluoromethyl- $\beta$ -diketones were unsuccessful. As described in Scheme 7, our synthesis began from LDA-catalyzed arylation of acetonitrile using commercially available aryl chlorides 42a and 56a at −78 °C to afford the requisite aryl acetonitriles 42b and 56b. A three-component Hantzsch ester-catalyzed reductive alkylation of 42b and 51b (commercially available), and 56b with 4-formylbenzenesulfonamide (50a) at 60 °C in ethanol quickly provided intermediates 42c, 51c, and 56c in good yield. Subsequent tosic acid-catalyzed cyclocondensation of the alkylated aryl acetonitriles 42c, 51c, and 56c with ethyl 2-hydrazinylthiazole-4-carboxylate (III) under microwave heating at 150 °C for 15 min in ethanol gave the critical intermediates 42d, 51d, and 56d in 60–77% yield. Our initial attempts to convert the amine functionality in compound 42d to a bromide or chloride were unsuccessful due to undesired halogenation of the thiazole at 5-position. However, using a sequential diazotization–iodination procedure of the amines 42d, 51d, and 56d in the presence of excess tosic acid with a premixed solution of KI/NaNO<sub>2</sub> in acetonitrile furnished the key intermediates 42e, 51e, and 56e in moderate yield. A fortuitous byproduct of this reaction was the des-amino (e.g., H-pyrazole) derivative (R<sub>3</sub> = 3,4-F), which after hydrolysis of the ethyl ester afforded compound 42. A portion of the intermediate 56e was

hydrolyzed with lithium hydroxide and purified by HPLC to obtain compound 56. With intermediates 51e and 56e in hand, the iodide was then subjected to Suzuki coupling with the appropriate boronic acid using SiliaCat DPP-Pd catalyst in the presence of aqueous Na<sub>2</sub>CO<sub>3</sub> in DME under microwave irradiation conditions at 130 °C to provide the aryl (51, R<sub>1</sub> = Me; 53, R<sub>1</sub> = Ph; 54, R<sub>1</sub> = 3-pyridine; 55, R<sub>1</sub> = 4-pyridine) after ester hydrolysis with LiOH. For the synthesis of 52, the iodide was displaced with cyanide by heating with CuCN in DMSO at 160 °C. For 57, Hartwig’s trifluoromethylator<sup>18</sup> (1,10-phenanthroline)(trifluoromethyl)copper(I) was used to install the requisite trifluoromethyl group. As with the above-mentioned analogs, the corresponding ethyl esters were hydrolyzed using LiOH to furnish analogs 52 and 57.

A convergent synthesis via cross coupling of the iodide in intermediate 51e or 56e was desired for more expedient analog synthesis; however, that approach failed for a number of desired analogs and more specifically with methylene cyclopropyl analogs 62 and 63. Therefore, a linear synthetic route was utilized, as shown in Scheme 8. Analogs 58 and 61 were synthesized using two different methods and rigorously analyzed to determine the correct regiochemistry of the respective products. The synthesis commenced from reaction of the requisite commercially available carboxylic acid with 1,2,3-benzotriazole to form N-acylbenzotriazole derivatives 58a and 62a. The next step involved coupling of the formed N-acylbenzotriazoles 58a and 62a to substituted acetophenones 59a and 61a via a magnesium bromide ethyl etherate-catalyzed soft enolization method in the presence of Hunig’s base to form 1,3-diketones 58b and 61b–63b in 60–69%. The 1,3-diketones 58b and 61b–63b were then efficiently alkylated with 4-(bromomethyl)benzenesulfonamide using cesium carbonate in DMSO at room temperature to generate intermediates 58c and 61c–63c. Intermediates 59c and 60c were readily obtained


Scheme 8. Synthesis of 58–63<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) 1,2,3-benzotriazole,  $\text{SOCl}_2$ ,  $\text{CH}_2\text{Cl}_2$ , 4 h, 91–100%; (b)  $\text{MgBr}_2\cdot\text{OEt}$ ,  $i\text{-Pr}_2\text{NEt}$ ,  $\text{CH}_2\text{Cl}_2$ , 12 h, 60–69%; (c) 4-(bromomethyl)benzenesulfonamide,  $\text{Cs}_2\text{CO}_3$ , DMSO, 1 h, 55–83%; (d) TMS-Cl, NCS,  $\text{CH}_2\text{Cl}_2$ , 0 °C to rt, 3 h, 73–94%; (e) 4-hydroxybenzenesulfonamide,  $\text{K}_2\text{CO}_3$ , DMSO, 50 °C, 1 h, 31–49%; (f)  $\text{TsOH}$ , EtOH, reflux, 12 h, 77–83% (mixture); (g)  $\text{LiOH}$ , THF–MeOH, 1 h.

from 58b–61b via chlorination with NCS followed by potassium carbonate assisted alkylation of the 4-hydroxybenzenesulfonamide. Toxic acid-catalyzed cyclocondensation of 2-alkylated 1,3-diketones 58c–63c with ethyl 2-hydrazinylthiazole-4-carboxylate hydrobromide III generated a mixture of both desired and undesired regioisomers. The ratio of the formation of the regioisomers varies depending on the nature of the substitution at R<sub>1</sub>. For example, the cyclization ratio of 58c–61c was 50:50, whereas it decreased to 10:90 desired to undesired for 62c and 63c. The desired isomer is slightly less polar (as judged by LC/MS analysis) and thus elutes as the second peak with reversed-phase (C18) chromatography. Of note, we were unable to separate these isomers efficiently with normal phase silica gel chromatography. The unseparated mixtures were then hydrolyzed with lithium

hydroxide in THF–methanol and separated in HPLC to give 58d–63d as first peak and 58–63 as second peak.

Analogs 64–68 were synthesized via functionalization at the corresponding ethyl esters at the thiazole ring as shown in Scheme 9. Heating the intermediate 64a with ammonia in a sealed tube gave the amide analog 64, which upon dehydration with trifluoroacetic anhydride (TFAA) in the presence of Hunig's base in dichloromethane followed by reaction with sodium azide and ammonium chloride gave the tetrazole analog 67. The intermediate 64a was obtained by the condensation of 37b and III as shown in the Scheme 3. LAH reduction of the intermediate 66a furnished analog 66 in high yield. Trifluoromethylation of the intermediate 51e with (1,10-phenanthroline)(trifluoromethyl)copper(I) in DMF as shown in Scheme 7 provided intermediate 66a. Manganese dioxide

Scheme 9. Synthesis of 64–68<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) NH<sub>3</sub>, EtOH, 60 °C, 18 h, 90%; (b) TFAA, *i*-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>; (c) NaN<sub>3</sub>, NH<sub>4</sub>Cl, DMF, 125 °C, 2 h; (d) LiAlH<sub>4</sub>, THF, 1 h; (e) MnO<sub>2</sub>, CHCl<sub>3</sub>, 2 h; (f) TMS-CF<sub>3</sub>, TBAF, THF, 4 h.

oxidation of the intermediate **68a** and subsequent trifluoromethyl addition to the aldehyde using TBAF and TMS-CF<sub>3</sub> provided analog **68**. The intermediate **68a** was readily obtained from intermediate **43c** using a Suzuki coupling with 4-(bromomethyl)benzenesulfonamideas shown in Scheme 4.


## ■ RESULTS AND DISCUSSION

At the outset of our medicinal chemistry campaign, the leading molecule reported in the literature, denoted as **1** (Figure 1), was the result of a fragment-based screen and structure-guided optimization campaign by AstraZeneca researchers.<sup>12</sup> While this compound had no appreciable cell-based activity (*vide infra*), it provided reproducible and robust biochemical inhibition of LDHA (IC<sub>50</sub> = 1.02 μM, Table 1). Despite conducting our screen with concentrations ranging from 13 nM to 57 μM, very little inhibition was observed across a library of approximately 400 000 compounds, an observation in agreement with other screening efforts against this target. However, our qHTS screening paradigm<sup>19</sup> enabled the identification of several compounds with modest potency (double digit μM) and partial efficacy (30–60% maximum response) but encouraging dose-dependent activity. One such compound, 2-(3-phenyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic acid (**5**), was thus identified as a putative LDH inhibitor and an attractive starting point for optimization based on its relatively small size (MW = 339 g/mol) presence of a carboxylic acid (could be docked to the pyruvate binding site) and chemical tractability. This compound has been previously reported as an EP<sub>1</sub> receptor antagonist; the compound was found to have no appreciable CYP inhibition and was stable in human plasma, suggesting good drug-like properties as a starting point for optimization.<sup>20</sup> However, **5** exhibited only modest potency (22.2 μM, Table 1) and efficacy (40–60%). It is worth noting this compound would likely have been discarded as inactive in a traditional single-dose HTS screening paradigm, as it only displayed inhibition at

concentrations concentrations above 20 μM, higher than those typically screened (e.g., 10 μM). However, the multiple dose qHTS format utilized at NCGC provides an opportunity to identify even modest inhibitors, making it an effective hit-identification platform for difficult targets like LDH.

Initial optimization efforts focused on systematic modifications to the CF<sub>3</sub> group to explore variations in substituent size, lipophilicity, and polarity, as shown in Table 1. Given the weak potency and efficacy of these early analogs, tractable SAR was not easily discernible, but some changes were clearly tolerated. Replacement of CF<sub>3</sub> (denoted as R<sub>1</sub>) with methyl (**6**), NH<sub>2</sub> (**7**), or NHAc group (**10**) all led to compounds with similar potency and efficacy as **5**. In contrast, replacement with an *i*-Pr (**8**) group or CHF<sub>2</sub> (**9**) group resulted in a significant loss in potency (>57 μM). Encouragingly, a drastic improvement in potency (>100-fold) was observed when the CF<sub>3</sub> group was replaced by OH, to provide the hydroxypyrazole compound (**11**), with an IC<sub>50</sub> of 0.144 μM. Additional hydroxyl analogs (**16–32**, Table 1) all exhibited submicromolar activity to further validate this SAR trend. Prior to the hydroxypyrazole discovery, we explored modifications to the phenyl group with representative examples (**12–15**) shown in Table 1. For these early analogs, a clear preference for halogens (e.g., Cl and F) at the 4-position emerged as exemplified by the potency difference between **12** and **13** (R<sub>2</sub> = 2-Cl-Ph and 3-Cl-Ph, respectively), compared to **14** and **15** (R<sub>2</sub> = 4-Cl-Ph and 4-F-Ph). On the basis of the improved potency of compound **11** (R<sub>1</sub> = OH), we held this group constant and expanded our SAR efforts of the phenyl group (R<sub>2</sub>) with representative examples (**16–32**) highlighted in Table 1. Single halogen substitutions with either F or Cl substitution (**16–19**) were all well-tolerated, with the 4-F derivative (**16**) possessing the most potent activity (IC<sub>50</sub> = 150 nM). Surprisingly, the preference for the 4-F group that we observed for the CF<sub>3</sub>-substituted pyrazoles did not translate to the hydroxypyrazole derivative, as compounds **18** and **19** (R<sub>2</sub> = 2-F-Ph and 3-F-Ph, respectively) had comparable potencies of

**Table 1.** LDHA Inhibition of 1, 5–32 with and without LDHA<sup>a</sup>



analog	R <sub>1</sub>	R <sub>2</sub>	IC <sub>50</sub> ± SD (μM)	
			LDHA (without EDTA)	LDHA (with EDTA)
1	NA	NA	1.02 ± 0.07	1.34 ± 0.15
5	CF <sub>3</sub>	Ph	22.2 ± 2.4 <sup>b</sup>	28.8 ± 1.9
6	Me	Ph	15.4 ± 12 <sup>b</sup>	>57
7	NH <sub>2</sub>	Ph	26.7 ± 3 <sup>b</sup>	>57
8	i-Pr	Ph	>57	>57
9	CHF <sub>2</sub>	Ph	>57	>57
10	NHAc	Ph	9.57 ± 1.8 <sup>b</sup>	>57
11	OH	Ph	0.144 ± 0.009	>57
12	CF <sub>3</sub>	2-Cl-Ph	>57	>57
13	CF <sub>3</sub>	3-Cl-Ph	>57	>57
14	CF <sub>3</sub>	4-Cl-Ph	26.6 ± 0.1	27.7 ± 1.9
15	CF <sub>3</sub>	4-F-Ph	23.4 ± 5.7	32.3 ± 2.1
16	OH	4-F-Ph	0.095 ± 0.001	>57
17	OH	3-Cl-Ph	0.168 ± 0.001	>57
18	OH	2-F-Ph	0.134 ± 0.001	>57
19	OH	3-F-Ph	0.162 ± 0.011	>57
20	OH	3-CF <sub>3</sub> -Ph	0.189 ± 0.001	>57
21	OH	3-OCF <sub>3</sub> -Ph	0.299 ± 0.001	>57
22	OH	4-OMe-Ph	0.229 ± 0.015	>57
23	OH	2-pyridine	1.02 ± 0.07	>57
24	OH	4-pyridine	0.669 ± 0.001	>57
25	OH	cyclohexyl	1.10 ± 0.08	>57
26	OH	1-naphthyl	0.213 ± 0.024	>57
27	OH	3,4-F-Ph	0.150 ± 0.001	>57
28	OH	3,4-Cl-Ph	0.106 ± 0.001	>57
29	OH	2,4-F-Ph	0.084 ± 0.001	>57
30	OH	3,5-F-Ph	0.110 ± 0.007	>57
31	OH	(3-Ph)-Ph	0.266 ± 0.001	>57
32	OH	3-(2-F-Ph)-Ph	0.095 ± 0.001	>57


<sup>a</sup>IC<sub>50</sub> values represent the half maximal (50%) inhibitory concentration as determined in the HTS assay (*n* = 3) using a 22-dose response in 1536-well format. <sup>b</sup>Maximum response was less than 50%, and thus IC<sub>50</sub> values should be considered as lower confidence.

0.134 μM and 0.162 μM. Similar potency was also observed for larger substituents on **20** (R<sub>2</sub> = 3-CF<sub>3</sub>-Ph) and **21** (R<sub>2</sub> = 3-OCF<sub>3</sub>), which had IC<sub>50</sub> values of 0.189 μM and 0.299 μM, respectively. Incorporation of an electron donating group (**22**, R<sub>2</sub> = 4-OMe-Ph) was tolerated, while replacement of the phenyl group with a 2-pyridine (**23**) or 4-pyridine (**24**) resulted in a modest loss of activity (IC<sub>50</sub> values of 1.02 and 0.669 μM, respectively). Changing the phenyl to a cyclohexyl group (**25**) gave potencies in line with the above-mentioned pyridine derivatives (IC<sub>50</sub> = 1.1 μM), while the naphthyl derivative (**26**) had an IC<sub>50</sub> value of 0.213 μM. Given data obtained from the preliminary SAR described above, we sought to further explore SAR of the pendent phenyl group at R<sub>2</sub>. Generally, bis-halogen substituted were well tolerated, as exemplified by analogs **27**–**30**, with most compounds having comparable or improved potency (IC<sub>50</sub> values ranging from 84 nM to 150 nM) relative to their monosubstituted counterparts. In an effort to explore the tolerance for larger hydrophobic groups, we synthesized

several biphenyl derivatives, with representative examples being **31** (R<sub>2</sub> = (3-Ph)-Ph) and **32** (R<sub>2</sub> = 3-(2-F-Ph)-Ph), which had IC<sub>50</sub> values of 266 nM and 95 nM, respectively. Though encouraged by the progress in improving the inhibitory potency of this series in the enzymatic assay, we were concerned that none of these compounds demonstrated inhibition of lactate production in cellular assays (data not shown), despite biochemical potencies approaching 100 nM.

A majority of hydroxypyrazole based compounds reproducibly demonstrated nonclassic dose–response curves. Namely, at most concentrations tested, these compounds yielded sigmoidal dose–response curves, often with 100% efficacy. However, at higher concentrations, inhibitory potency was being diminished.

One explanation for these aberrantly shaped IC<sub>50</sub> curves could be that at higher concentrations, the compounds were not soluble and were precipitating out. However, these compounds have very good aqueous solubility, and no evidence of insolubility was observed. Alternatively, the compounds being tested might also contain a lower potency activator of LDHA that would overcome the inhibition at higher concentrations. Multiple studies have previously reported that several isoforms of LDHA, including human, demonstrate metal-binding activity, notably with divalent cations such as Mn<sup>2+</sup>, Co<sup>2+</sup>, and Zn<sup>2+</sup>. Incubation or complexation with certain metals has been reported to maintain or potentiate LDHA activity, while incubation with chelating agents such as EDTA has been found to reversibly inhibit activity of the yeast LDHA isoform.<sup>21</sup> To test this hypothesis, the biochemical assay was adapted and rerun in the presence of 100 μM EDTA to chelate any (trace) metal present in the assay. Notably, in the presence of EDTA, most of the hydroxypyrazole derivatives (**11**, **16**–**32**) did not just lose the aberrant portion of the IC<sub>50</sub> curve but instead lost almost all inhibitory activity, with many demonstrating IC<sub>50</sub> values of >57 μM (Table 1). In contrast to the hypothesis being tested, this result suggested that inhibition by the hydroxypyrazole compounds either required or was potentiated by the presence of a trace metal. The activity of the original hit **5** and the CF<sub>3</sub>-pyrazole analogs **14** and **15** was unaffected by EDTA, which suggested that inhibition by this chemotype requires binding to LDHA that can be enhanced by trace metals. Given the potential for metal coordination by the hydroxypyrazole, in combination with the thiazole nitrogen or sulfur and the carboxylic acid moiety, additional studies to characterize the source and influence of trace metals in this assay were conducted (see below for additional details). These experiments pointed to the assay buffer as the source of metal contamination, with trace amounts of Zn<sup>2+</sup> being the most likely contaminant affecting the assay. Dialysis of individual assay components suggested that the trace metal was present in the commercial Tris buffer used for the assay rather than in the stocks of LDHA enzyme or inhibitor (data not shown). Also, testing with several divalent cations demonstrated that activity of the hydroxypyrazole inhibitors showed a dose-dependent potentiation with increasing metal concentration and that the compounds were potentiated most strongly by Zn<sup>2+</sup> (added as zinc chloride, data not shown). Metal impurities causing direct effects on LDHA has been reported previously, as Ward et al. found that the presence of silver resulted in inhibition of LDHA activity.<sup>12</sup> Given these observations, we sought to obtain the crystal structure of this class of inhibitor bound to LDHA and carried our subsequent rounds of LDHA inhibition assays under two conditions to fully



**Figure 2.** (A) Crystal structure of inhibitor **27** bound to LDHA in complex with zinc. The inhibitor is shown in sticks with salmon-colored carbons. The protein is shown in ribbon representation, and the metal zinc is shown as a magenta sphere. A water molecule (red sphere) and protein residues R168, H192, and T247 (yellow-colored carbons) are coordinated with Zn or form H-bonding interactions with the inhibitor. PDB code is 5W8I. (B) Inhibitor **33** docked in the binding pocket of LDHA and overlaid with **4** (purple-colored carbons). The benzyl sulfonamide moiety is shown with magenta-colored carbons.

account for any metal coordination effects: in the presence of 100  $\mu\text{M}$  EDTA and in the presence of 100  $\mu\text{M}$   $\text{ZnCl}_2$ .

The X-ray crystal structure of inhibitor **27** bound to human LDHA provided insight into the mechanism by which zinc enhanced inhibitor potency. The complex was obtained by transferring crystals grown with sodium malonate into a drop without malonate but which contained citrate. To this solution, **27** and  $\text{ZnCl}_2$  were added to a final concentration of 2 mM and allowed to soak for 3 days before crystals were harvested and flash frozen. The 1.95 Å crystal structure contained compound **27** bound to three of the four subunits of the LDHA tetramer, with malonate occupying the catalytic site of the remaining monomer. The inhibitor is anchored by a salt bridge interaction between its carboxylate and the guanidinium group of R168 (Figure 2A). A hydrogen bond also is observed between the carboxylate and the side chain of T247. The thiazole ring and the plane of N137 stack, and the distal difluorophenyl picks up hydrophobic interactions with the planes of P138 and Q99. The zinc is coordinated by H192, one water molecule, and three atoms in-plane from **27** (the OH of the carboxylate, the NH of the thiazole, and the OH of the hydroxylpyrazole group) providing a clear rationale for the additional potency conferred by zinc (Figure 2A, PDB code 5W8I). Our initial LDHA-inhibitor complexes were formed in the absence of NADH; however, the X-ray structure showed room below the inhibitor for occupancy by cofactor. Subsequent structures included NADH, which did not alter the position of the inhibitor but did lead to substantial increases in binding affinity as determined by SPR (vide infra).

With this experimental soaking method, we were then able to determine a 1.8 Å crystal structure of the weaker  $\text{CF}_3$ -containing inhibitor **15** (Supporting Information Figure 2, PDB code 5W8H). It was clear from the electron density in this structure that the binding mode of **15** is essentially the same as that of **27**, with the carboxylate making the anchoring salt bridge interaction with R168 and the thiazole rings being superimposable between the two structures. Interestingly, the published LDHA inhibitor NHI-2 was predicted to adopt similar binding interactions in the active site, with the carboxylate interacting with R168 (R169 in ref 10) and the trifluoromethyl pointing to H192 (H193 in ref 10). The trifluoromethyl is well ordered in the crystal structure, but without the planar coordination enforced by zinc and with the

increased steric bulk of the trifluoromethyl group (as compared to the hydroxyl), the pyrazole is now tilted  $\sim 30^\circ$  out of plane. In the absence of zinc, H192 now makes two hydrogen bonds directly to the carboxylate and thiazole nitrogen of **15**.

Despite the apparent requirement of a coordinating zinc ion for optimal inhibitory potency, the similar binding orientation observed for **15** and the ability of **15** to adjust in order to fill the binding site and directly interact with H192 suggested that potent analogs could be designed that would bind without zinc.

A different LDHA inhibitor crystal structure published by Genentech (**4**, Figure 1, PDB code 4M49) revealed a comparable binding orientation as **27** in our series<sup>14b</sup> and suggested an opportunity to design a hybrid molecule. The aminophenylsulfonamide substituent of **4** was reported to make numerous critical hydrogen bonds with the enzyme (i.e., Asp140, Glu191, and Ile141). Indeed, molecular modeling overlay of the two structures (Figure 2B; purple = **4**; tan and magenta = postulated benzylsulfonamide analog of our chemotype) suggested that incorporation of a similar benzylsulfonamide substituent onto the 4-position of the pyrazole ring could extend into the same pocket and pick up these same interactions without significantly disrupting the binding interactions of **27** (Figure 2B). Toward this end, compound **33** was synthesized, tested, and found to have an  $\text{IC}_{50}$  of 672 nM in the presence of EDTA (100  $\mu\text{M}$ ), as shown in Table 2. This compound represented the first sub- $\mu\text{M}$  inhibitor of this chemical series that did not absolutely require zinc for potent inhibition. However, since this molecule retained the hydroxylpyrazole moiety, its activity could still be potentiated by zinc, leading to low nM inhibition (data not shown). Following this breakthrough, subsequent rounds of testing were conducted with EDTA in the assay buffer to ensure that metal-independent inhibition was driving SAR and further medicinal chemistry optimization.

Concurrently, GSK reported the discovery and biological characterization of **2**, the first single/double-digit nM LDHA inhibitor with appreciable cell-based activity (lactate production assay), though the compound's PK properties ultimately precluded its use *in vivo*.<sup>12</sup> Given this, **2** was used as a benchmark compound for comparison purposes in both biochemical (Table 2) and cell-based assays (Table 5). Evaluation of parameters such as CLogP, ligand lipophilic efficiency (LLE), and ligand efficiency (LE) for prior art

**Table 2. LDHA Inhibition of 33–63 with Comparators 2 and 3<sup>a</sup>**


analog	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	X	LDHA (w/EDTA)	
						IC <sub>50</sub> ± SD (μM)
2	NA	NA	NA	NA	0.038 ± 0.004	
3	NA	NA	NA	NA	0.424 ± 0.049	
33	OH	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3,4-F	CH <sub>2</sub>	0.672 ± 0.077	
34	OH	3-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3,4-F	CH <sub>2</sub>	>57	
35	OH	Phenyl	3,4-F	CH <sub>2</sub>	>57	
36	OH	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Br	CH <sub>2</sub>	2.37 ± 0.001	
37	OH	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	0.349 ± 0.023	
38	OH	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-(2-F-Ph)	CH <sub>2</sub>	0.754 ± 0.087	
39	OH	4-(SO <sub>2</sub> NHMe)-Ph	3-Ph	CH <sub>2</sub>	>57	
40	OH	4-(CONH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	>57	
41	OH	4-(COOH)-Ph	3-Ph	CH <sub>2</sub>	33.8 ± 5.5 <sup>b</sup>	
42	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3,4-F	CH <sub>2</sub>	0.095 ± 0.001	
43	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.176 ± 0.032	
44	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	0.038 ± 0.001	
45	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	O	0.124 ± 0.008	
46	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	NH	0.057 ± 0.004	
47	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	NH	0.091 ± 0.006	
48	H	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	C(O)NH	>57	
49	H	•N(SO <sub>2</sub> NH <sub>2</sub> ) <sub>2</sub>	H	CH <sub>2</sub>	17.3 ± 8.1	
50	H	•N(SO <sub>2</sub> NH <sub>2</sub> ) <sub>2</sub>	H	CH <sub>2</sub>	>57	
51	Me	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.042 ± 0.001	
52	CN	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.115 ± 0.130	
53	Ph	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.139 ± 0.009	
54	3-pyr	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.349 ± 0.024	
55	4-pyr	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	6.23 ± 0.79	
56	NH <sub>2</sub>	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	0.065 ± 0.011	
57	CF <sub>3</sub>	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	0.053 ± 0.001	
58	•Δ	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.019 ± 0.001	
59	•Δ	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	O	0.065 ± 0.050	
60	•Δ	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	O	0.110 ± 0.008	
61	•Δ	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	0.027 ± 0.001	
62	•Δ	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	H	CH <sub>2</sub>	0.009 ± 0.001	
63	•Δ	4-(SO <sub>2</sub> NH <sub>2</sub> )-Ph	3-Ph	CH <sub>2</sub>	0.032 ± 0.002	

<sup>a</sup>IC<sub>50</sub> values represent the half maximal (50%) inhibitory concentration as determined in the HTS assay (*n* = 3) using a 22-dose response in 1536-well format. <sup>b</sup>Maximum response was less than 50%, and thus IC<sub>50</sub> values should be considered as lower confidence.

compounds 2 and 3 revealed an apparent preference for higher lipophilic character, with ClogP values of 7.75 and 4.79 for 2 and 3, respectively (see Supporting Information Table 2). In comparison, compound 5 and further optimized analog 33 have ClogP values of 4.18 and 3.10, respectively. As a result, there is a marked improvement in LLE for 33 (3.07) over 5 (0.36) and prior art compounds 2 (−0.33) and 3 (1.58), as shown in Table S2. To further explore the SAR of our benzylsulfonamide-containing scaffold, we obtained high-resolution (1.6 Å) crystal structures of 33 with (PDB code SW8K) and without (PDB code SW8J) the NADH cofactor (Figure 3A). As anticipated from the significantly improved inhibitory potency, the sulfonamide moiety formed critical hydrogen bonds with Asp140, Glu191, and I141. Compound 2 was less potent when inhibition assays were carried out with 10× higher NADH concentrations, whereas inhibition with our series of inhibitors was largely unaffected by this change. However, the crystal structure of the ternary complex with NADH and 33 suggested that inhibitor binding may be enhanced by the presence of NADH (Figure 3B). Results from surface plasmon resonance (SPR) studies (vide infra) substantiated this hypothesis.

The importance of the sulfonamide and tolerance for modification of this region was evaluated via the synthesis of several analogs, with illustrative examples shown in Table 2. Moving the sulfonamide group to the 3-position of the phenyl ring (34), removing it completely (35), or adding a methyl to the amine (39) or an amide (40) resulted in loss of inhibitory activity (IC<sub>50</sub> > 57 μM). Moreover, replacing the sulfonamide with a carboxylic acid (41) led to decrease in potency with an IC<sub>50</sub> value of ~34 μM. Given the tolerance and apparent benefit of biphenyl derivatives (Table 1), the corresponding 3-Ph (37) and 3-(2-F-Ph) (38) analogs were prepared and found to have IC<sub>50</sub> values of 349 nM and 755 nM, respectively. As the hydroxypyrazole scaffold retains the ability to chelate Zn (and likely other metals), we sought to explore pyrazole substituents to identify analogs that alleviated this concern. The first series of analogs (42–50) removed the hydroxyl group altogether (R<sub>1</sub> = H). Encouragingly, several of these compounds (e.g., 42) exhibited double digit nM IC<sub>50</sub> values, comparable to the potency of (2). As observed previously, the biphenyl moiety (44; R<sub>3</sub> = 3-Ph) was beneficial for improved inhibition in this series as well (IC<sub>50</sub> = 38 nM). However, given the sufficient activity and ease of synthesis, the simple phenyl derivative (e.g., 43) was frequently used to explore further SAR. Accordingly, modification of the benzylmethylen group to either an oxygen (45) or nitrogen (46 and 47) was well tolerated, but the analogous amide (48) was not, with IC<sub>50</sub> values of 124 nM, 57 nM, 91 nM, and >57 μM, respectively. Moreover, replacement of the phenyl group with a piperazine moiety (49) led to a significant loss of potency (IC<sub>50</sub> = 17.3 μM), as did incorporation of the 4-aminophenylsulfonamide group (50; IC<sub>50</sub> ≥ 57 μM). Taken together, these data support the notion that this region is critical for potent inhibition and that tolerance for structural modification is limited.

Additional modifications to the pyrazole substituent (R<sub>1</sub> in Table 2) were explored next, as exemplified by analogs 51–63. Installation of a methyl group (51, IC<sub>50</sub> = 0.042 μM and nitrile (52 IC<sub>50</sub> = 0.115 μM) resulted in increased potency compared to the parent hydroxypyrazole derivative (33). This region did demonstrate some tolerance (albeit, with weaker potency) for larger hydrophobic groups, with compound 53 (R<sub>1</sub> = Ph) possessing similar inhibition (IC<sub>50</sub> = 0.139 μM). Interestingly,




**Figure 3.** (A) Crystal structure of LDHA bound with 33. The inhibitor is shown in sticks, and the protein is shown in surface representation. Key protein residues Asp140, Glu191, and Ile141 form H-bonding interactions with the sulfonamide moiety as shown by dotted red lines. PDB code is SW8J. (B) Overlay of inhibitor 33 (salmon) and 4 shown in purple (Figure 1) bound in the binding pocket of LDHA.

the 3-pyridine (**54**) and 4-pyridine (**55**) derivatives had significantly different potencies of 349 nM and 6.23  $\mu$ M, respectively, suggesting a deleterious interaction of the pyridine nitrogen when in the 4-position (or beneficial interaction of the nitrogen in the 3-position). Incorporation of the an amino group (**56**), and the original CF<sub>3</sub> group (**57**) were both well tolerated with IC<sub>50</sub>s values of 65 nM and 53 nM, respectively. Next, we incorporated a cyclopropyl group (**58–61**) and later a methylene cyclopropyl group (**62** and **63**) that were generally more potent than previous analogs, displaying potencies ranging from 9 to 110 nM. Extension of the cyclopropyl group with a methylene spacer enabled a potential pseudo  $\pi$ – $\pi$  interaction between the  $\pi$ -like character of the cyclopropyl group and an active-site tyrosine (Tyr238), as shown in Supporting Information Figure 3, PDB code SW8L. We also tested the respective regioisomers (**61d** and **63d**), and neither of them showed any appreciable activity in enzymatic or cell-based assays (data not shown). Notably, while the biochemical potencies of the cyclopropyl and methylenecyclopropyl derivatives were not significantly different from other potent analogs, cellular assays provided a greater disparity in activity (vide infra).

Thiazolecarboxylic acid replacements were investigated. Efforts to replace the thiazole with any other ring structure, including oxazole, pyridine, and other heterocycles, were all markedly detrimental to activity (data not shown). Finally, to determine the quantitative importance of the anchoring interaction between the carboxylic acid moiety and R168, we synthesized the corresponding amide (**64**), ethyl ester (**65**), primary alcohol (**66**), tetrazole (**67**), and secondary alcohol (**68**) derivatives. All showed a marked loss of potency (Table 3). The amide (**64**) and primary alcohol (**66**) analogs showed modest inhibition of 27.7  $\mu$ M and 25.5  $\mu$ M, respectively, while **65**, **67**, and **68** were not inhibitory (IC<sub>50</sub>  $\geq$  57  $\mu$ M), illustrating the requirement of the carboxylic acid moiety to maintain potent inhibition.

Concurrently, Genentech published several papers describing the discovery and optimization of 3 (Figure 1) as a potent LDHA inhibitor.<sup>14c</sup> Compound 3 inhibited LDHA in our assay with an IC<sub>50</sub> of 424 nM, substantially less potent than the reported values (IC<sub>50</sub> < 10 nM). The discrepancy is likely due to differences in the assay conditions and demonstrates the importance of conducting head-to-head comparisons of reference compounds when drawing conclusion about biological activity.

**Table 3. LDHA Inhibition of 64–68<sup>a</sup>**



analog	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	LDHA (with EDTA) IC <sub>50</sub> ± SD ( $\mu$ M)
<b>64</b>	CONH <sub>2</sub>	OH	3-Ph	27.7 ± 1.9
<b>65</b>	COOEt	CF <sub>3</sub>	3-Ph	>57
<b>66</b>	CH <sub>2</sub> OH	CF <sub>3</sub>	H	25.5 ± 6.2 <sup>b</sup>
<b>67</b>	tetrazole	OH	3-Ph	>57
<b>68</b>	CH(OH)CF <sub>3</sub>	H	H	>57

<sup>a</sup>IC<sub>50</sub> values represent the half maximal (50%) inhibitory concentration as determined in the HTS assay ( $n \geq 3$ ) using a 22-dose response in 1536-well format. <sup>b</sup>Maximum response was less than 50%, and thus IC<sub>50</sub> values should be considered as lower confidence.

Selectivity of representative analogs was determined by assessing their biochemical activity against another LDH isozyme, LDHB, and two “off-target” dehydrogenases, malate dehydrogenase (MDH) and isocitrate dehydrogenase 1 (IDH1). While there was negligible activity against both MDH and IDH1, most of the analogs revealed similar potency for LDHB when compared to LDHA (Table 4).

To determine the cellular activity of analogs, we tested them in a high-throughput fluorescence/absorbance-based lactate production assay (1536-well) using the A673 human sarcoma and MiaPaCa-2 human pancreatic cancer (see Table 5) cell lines in 22-point dose–response. Both cell lines demonstrate a highly glycolytic phenotype with robust production of lactate, making them an ideal choice for these assays. 2, which was reported to exhibit sub- $\mu$ M inhibition of lactate production, demonstrated an IC<sub>50</sub> of 14.5  $\mu$ M, a result consistent across a number of cell lines. Though the reason for this discrepancy is unclear (difference in assay platforms may be one possibility), this observation underscored the need for novel inhibitors with greater efficacy in cells. Compound 3 exhibited better potency in this cell-based lactate production assay than did 2, with an IC<sub>50</sub> of 1.44  $\mu$ M. Compounds from our chemical series, e.g., **61** and **63**, exhibited comparable potency in these cell lines. However, for many of the representative compounds shown in Table 5, the potent biochemical inhibition translated into little to no cell-based activity. To determine if cell permeability was a

**Table 4.** Selectivity against LDHB and Other Dehydrogenases<sup>a</sup>

analog	IC <sub>50</sub> (μM)			
	LDHA	LDHB	MDH	IDH1wt
1	1.34	9.20	>57	>57
2	0.038	1.15	37.8	>57
3	0.424	0.441	>57	>57
33	0.672	0.724	>57	>57
36	2.37	1.51	37.8 <sup>b</sup>	>57
37	0.349	0.424	>57	47.4 <sup>b</sup>
38	0.754	0.911	33.7	>57
42	0.095	0.129	>57	>57
43	0.177	0.204	>57	>57
44	0.038	0.049	48.6	47.4
46	0.057	0.078	37.8 <sup>b</sup>	>57
47	0.091	0.096	>57	>57
54	0.349	0.259	>57	>57
55	6.23	2.82	>57	>57
56	0.065	0.075	26.8 <sup>b</sup>	>57
57	0.053	0.062	48.6	33.5 <sup>b</sup>
58	0.019	0.020	37.8	>57
60	0.110	0.119	>57	26.6
61	0.027	0.020	42.4	33.5
62	0.009	0.008	>57	47.4
63	0.032	0.027	37.8 <sup>b</sup>	29.8

<sup>a</sup>IC<sub>50</sub> values represent the half maximal (50%) inhibitory concentration as determined in the HTS assay (*n* = 3). <sup>b</sup>Maximum response was less than 50%, and thus IC<sub>50</sub> values should be considered as lower confidence.

limiting factor, we measured the intracellular concentration of several inhibitors using LC–MS/MS analysis. The compounds


appeared to reach appreciable intracellular levels (high μM) and thus well in excess of their respective biochemical IC<sub>50</sub> values (data not shown). Differential lactate inhibition by compounds with comparable structures and presumably physicochemical properties (e.g., 44 R<sub>1</sub> = H and 61 R<sub>1</sub> = cyclopropyl) further suggested permeability was not the main barrier to cellular efficacy; these compounds demonstrated biochemical IC<sub>50</sub> values of 38 nM and 27 nM, respectively, yet 61 was approximately 15-fold more potent in the lactate production assay (0.983 μM (61) vs 15.2 μM (44)). Moreover, the most potent compound in the lactate assay was compound 63 (IC<sub>50</sub> = 0.517 μM), which possessed a methylene cyclopropyl group at R<sub>1</sub> and 3-Ph group at R<sub>3</sub>, yet was less potent in the biochemical assay than the corresponding cyclopropyl derivative (61). The cytotoxicity of compounds against these glycolytic cell lines tracked reasonably well with inhibition of lactate production, consistent with an on-target mechanism of cell killing. All compounds that demonstrated appreciable inhibition of lactate production (IC<sub>50</sub> < 4 μM; 3, 60–63) also exhibited modest cytotoxicity (IC<sub>50</sub> = 1–30 μM) in a 48 h CellTiter-Glo assay in A673 and MiaPaCa-2 cells (see Table 5).

In an effort to probe this roughly 100-fold offset between biochemical and cellular potencies, we considered the concept of drug–target residence time which has been championed by Copeland and others.<sup>22</sup> While this concept is usually brought up in the context of in vivo efficacy, it has been reported to impact cellular efficacy as well.<sup>23</sup> Given the high concentration of intracellular LDH (estimated to be in the range of 2–17 μM),<sup>11,24</sup> we reasoned that longer residence times might be necessary to achieve significant, sustained decreases in cellular LDH function. As noted above, this approach could also be beneficial in vivo, since drug concentration in systemic

**Table 5.** Cell-Based Activity of Representative Analogs

analog	A673 cells			MiaPaCa-2 cells		
	IC <sub>50</sub> ± SD (μM) <sup>a</sup>		IC <sub>50</sub> (μM) <sup>c</sup>	IC <sub>50</sub> ± SD (μM) <sup>a</sup>		IC <sub>50</sub> (μM) <sup>c</sup>
	lactate inh	cytotoxicity	long-term growth inh	lactate inh	cytotoxicity	long-term growth inh
1	>57	>57	>20	>57	>57	>20
2	14.5 ± 5.7	>57	0.84	12.6 ± 3.6	28.4 ± 11.2 <sup>b</sup>	1.37
3	1.44 ± 0.09	2.63 ± 0.3		0.877 ± 0.059	1.24 ± 0.08	
33	>57	>57		>57	>57	
36	>57	>57		>57	>57	
37	26.8 ± 3.1	>57		27.7 ± 1.9 <sup>b</sup>	>57	
38	30.0 ± 3.5 <sup>b</sup>	>57		29.9 ± 0.1 <sup>b</sup>	>57	
42	30.8 ± 2.1 <sup>b</sup>	>57		>57	>57	
43	25.2 ± 19.4 <sup>b</sup>	>57		33.5 ± 0.1 <sup>b</sup>	>57	
44	15.2 ± 3.2	>57	>20	9.88 ± 1.26	>57	>20
46	19.9 ± 4.5	>57		7.24 ± 0.47	>57	
47	26.8 ± 3.1	>57		22.4 ± 1.8	>57	
54	16.5 ± 6.2	>57		26.6 ± 0.1 <sup>b</sup>	>57	
55	>57	>57		>57	>57	
56	9.45 ± 0.01	>57		17.7 ± 6.6	>57	
57	4.35 ± 1.21	>57	>20	4.80 ± 2.47	>57	>20
58	14.7 ± 3.6	>57		17.5 ± 1.2	>57	
60	1.92 ± 0.43	25.8 ± 3.0		1.96 ± 0.13	28.3 ± 7.1	
61	0.983 ± 0.335	13.9 ± 0.9	21.09	1.34 ± 0.15	18.9 ± 1.3	8.00
62	3.37 ± 0.39	24.8 ± 1.6	>20	5.12 ± 0.33	24.9 ± 1.6	>20
63	0.517 ± 0.088	2.90 ± 0.3	2.23	0.854 ± 0.059	3.96 ± 0.68	1.21

<sup>a</sup>IC<sub>50</sub> values represent the half maximal (50%) inhibitory concentration as determined in the HTS assay (*n* = 3). <sup>b</sup>Maximum response was less than 50%, and thus IC<sub>50</sub> values should be considered as lower confidence. <sup>c</sup>IC<sub>50</sub> values represent average of two assay replicates.



**Figure 4.** Decrease in glycolytic flux caused by LDH inhibitors in A673 cells. The glycolysis stress test was performed in A673 cells. The extracellular acidification rate (ECAR) over time, cellular basal ECAR, was measured, and then (A) 3, (B) 61, or (C) 63 was injected in a dose–response manner. After 40 min, subsequent injections of glucose (10 mM), oligomycin (O at 1  $\mu$ g/mL, reaching maximal glycolytic capacity), and 2-deoxyglucose (2-DG at 50 mM, inhibition of glycolysis) were made. (D) Quantification of the maximal ECAR (% from control of maximal ECAR minus ECAR with 2-DG) of increasing concentrations of the five LDH inhibitors.

circulation decreases with time and LDH is an abundant, ubiquitously expressed protein. Thus, we obtained SPR data with representative compounds to examine this hypothesis.

For the initial study, four compounds (2, 33, 61, and 63) were chosen based on their biochemical potency and differential activity in the cell-based lactate output assay.<sup>25</sup> Compounds from the internal chemical series displayed more potent binding affinities and longer off-rates ( $k_{off}$ ) in the presence of saturating NADH (500  $\mu$ M) than without, supporting the hypothesis that arose from the initial crystallography studies. However, 2 was found to have greater binding affinity in the absence of NADH ( $K_D = 1.7$  nM versus 59 nM with NADH), in agreement with its reported NADH competitive mechanism of inhibition. Because inhibition of LDH in cells results in increased intracellular concentrations of NADH, a mechanism of inhibition that produces increased affinity for LDH and greater duration of target occupancy when NADH concentrations are elevated should be a more efficacious mechanism than a NADH-competitive one. The  $K_D$  values for three representative compounds and a comparator (2, 33, 61, and 63) in the presence of NADH were 59 nM, 370 nM, 0.33 nM, and 0.11 nM, respectively. Interestingly, the off-rates and corresponding residence times ( $\tau$ ) [calculated as  $1/k_{off}(\text{s}^{-1})$ ] tracked well with the cellular potency [ $2 (\tau = 8 \text{ s}), 33 (\tau = 0.5 \text{ s}), 61 (\tau = 470 \text{ s}),$  and  $63 (\tau = 1200 \text{ s})$ ]. While rational optimization of drug–target residence time has been reported,<sup>26</sup> it can be difficult to delineate such structure–activity relationships, as minor structural changes may lead to surprisingly large differences in binding properties.<sup>27</sup> As such, SPR analysis of binding kinetics will be incorporated into our future SAR efforts as an important optimization parameter and compound attribute, alongside biochemical potency, cell-based potency, and ADME properties.

The glycolysis stress test (GST) was performed on the Seahorse XF analyzer in order to assess changes in glycolytic flux resulting from LDH inhibition (Figure 4). This assay


measures the net glycolysis-dependent proton production in the cells and, as such, is a marker of the inhibition of glycolysis consequent on LDH inhibition. It is anticipated that as LDH inhibition increases with the concentration of compound, the reserve biochemical capacity of the enzyme for glycolysis is exceeded, resulting in a depletion of NAD<sup>+</sup> and, ultimately, inhibition of the entire pathway. The extracellular acidification rate (ECAR) was monitored in A673 cells before and after injection of five compounds (2, 3, 33, 61, and 63) over a range of concentrations. These data show a clear concentration-dependent decrease in the glycolytic flux (Figure 4A–C), consistent with the anticipated inhibition of the proton efflux into the media. In addition, the capacity of the cell to switch from oxidative phosphorylation to glycolysis following injection of oligomycin, a specific inhibitor of ATP-synthase, is suppressed by all LDH inhibitors. This can be clearly seen from the quantification of % maximal ECAR (maximal glycolytic capacity) in A673 cells for a panel of five LDHA inhibitors, which shows that the inhibitory potency order is  $63 > 61 > 33 > 3 > 2$ , which correlates with the cell-based lactate inhibition assay (see Table 5), with the exception of 33. As shown in Figure 4D, the leading compounds 63 and 61 completely inhibit lactate production/extracellular acidification at concentrations of 2 and 5  $\mu$ M, respectively, corroborating that the incorporation of biphenyl and cyclopropyl (61) or a methylene cyclopropyl (63) improved LDH inhibition in cell-based *in vitro* assays.

To obtain additional evidence of cellular target engagement of LDHA by our compounds, CETSA (cellular thermal stabilization assay), a technique that translates the principles of biochemical thermal shift assays to a cellular context was adapted and optimized for LDHA in a number of cell lines.<sup>28</sup> Accordingly, a panel of representative compounds were tested in A673 cells, spanning a wide range of potencies (Supporting Information Figure 1a–e). Cellular binding and stabilization of LDHA were observed with a number of top LDHA inhibitors (Table 6) at concentrations as low as 100 nM. Compounds 62

Table 6. CETSA LDHA Stabilization in A673 Cells

analog	LDHA inh	lactate inh	CETSA: cellular LDHA stabilization		
	IC <sub>50</sub> ( $\mu$ M)	IC <sub>50</sub> ( $\mu$ M)	EC <sub>50</sub> ( $\mu$ M) <sup>a</sup>	max stab <sup>b</sup> (normalized)	AUC <sup>c</sup> (normalized)
1	1.020	>57	1.60	64.8	62.08
2	0.038		8.18	52.4	43.22
3	0.424	12.60	1.26	79.0	72.96
5	22.200		>100	8.5	13.84
33	0.672	>57	3.53	47.9	53.66
44	0.038	9.88	2.56	100.0	89.77
57	0.053	4.80	>100	41.6	26.76
61	0.027	1.34	0.25	63.0	70.66
62	0.009	5.12	0.07	70.8	100.00
63	0.032	0.85	0.17	69.9	81.95

<sup>a</sup>EC<sub>50</sub> values represent the half maximal (50%) concentration (the concentration needed to stabilize half of the detectable LDHA protein at a set melting temperature) as determined by CETSA. <sup>b</sup>Maximum stabilization values represent the highest amount of stabilized LDHA detected for each sample, as measured by Western blot band intensity. These values are scaled against the band with the greatest amount of stabilized LDHA (maximum response of 44) to provide a relative measure of target binding. <sup>c</sup>Area-under-the-curve (AUC) values demonstrate the total amount of LDHA stabilized by each compound across all concentrations, scaled against the AUC of the compound with the greatest total amount of LDHA stabilization (62) to provide a relative measure of LDHA engagement.



**Figure 5.** Incucyte long-term cellular growth data. (A) Cellular confluence of MiaPaCa-2 cells treated with LDHA inhibitors at 2.22  $\mu$ M over 120 h. (B) Dose-response relative growth of MiaPaCa-2 cells treated with 63 for 120 h. Relative growth of (C) MiaPaCa-2 and (D) A673 cells treated with LDHA inhibitors for 120 h.

and 63 were particularly potent at stabilizing LDHA in A673 cells. Given its relatively direct readout on target engagement, we examined the relationship of CETSA-based activity to other measures of LDHA inhibitor potency. Though the compounds with the most potent activity against LDHA in the biochemical assay were also among the most potent in the CETSA assays, no clear correlation emerged between the cellular stabilization of LDHA via CETSA and either biochemical or cellular activities of these molecules. Interestingly, 1 demonstrated cellular stabilization of LDHA, despite showing no activity in any prior cell-based LDHA assays. Conversely, 57 demonstrated potent inhibition of LDHA and moderate inhibition of cellular lactate, yet displayed comparatively little stabilization of LDHA via CETSA, and no toxicity or growth inhibition of either cell line tested. As such, CETSA-measured LDHA-

binding was utilized as one marker of activity in a panel of many.

Having developed compounds with potent inhibition of LDH (<20 nM) and lactate production (1–2  $\mu$ M) and with robust target engagement, as assessed via SPR and CETSA, we investigated the cytotoxicity of these agents against MiaPaCa-2 and A673 cells. Initial efforts utilized a 48 h cytotoxicity assay using ATP content as a viability surrogate (CellTiter-Glo), and longer-term effects on cell growth were studied by monitoring confluence over 5 days using an Incucyte ZOOM (see Table 5). Early analogs had minimal to no effect on cell proliferation, whereas 3 and 63 demonstrated suppression of cell growth over time (Table 5, Figure 5A). Dose-response treatment of MiaPaCa-2 cells with 63 showed effects on cellular proliferation at concentrations as low as 250 nM and with nearly complete arrest of cell growth at 20  $\mu$ M (Table 5, Figure 5B). Area-

under-the-curve (AUC) analysis was conducted on MiaPaCa2 and A673 dose-response data to enable comparison of LDH inhibitors (**Figure 5C** and **Figure 5D**, respectively); **3** and **63** both exhibited single digit  $\mu\text{M}$  activity in both A673 and MiaPaCa-2 cells. While inhibition of cell proliferation itself was not exceptionally potent, it was encouraging that cytotoxicity was positively correlated with target potency (enzymatic and cellular lactate output), suggesting that the effects were target-mediated.

To help define the utility of these initial compounds for proof-of-concept animal studies, we performed *in vivo* PK and *in vitro* ADME studies on representative inhibitors **61** and **63** (**Table 7**). Tier 1 ADME profiling comprised rat liver

**Table 7. Representative ADME Data for 61 and 63<sup>a</sup>**

analog	$T_{1/2}$ (min)			$T_{1/2}$ (min)	
	MLM	HLM	mouse hepatocytes	PAMPA permeability ( $10^{-6}$ cm/s)	kinetic solubility ( $\mu\text{g}/\text{mL}$ )
<b>61</b>	321	414	268	1	>82
<b>63</b>	444	206	239	8	>82

<sup>a</sup>Aqueous kinetic solubility (PBS buffer) and PAMPA permeability were conducted at NCATS. Mouse plasma stability studies were conducted at Pharmaron Inc. and involved five time points. The microsomal stability data [mouse liver microsomes (MLM), human liver microsomes (HLM), and mouse hepatocytes] were conducted at QuintaraBio and represent the stability in the presence of NADPH and UDPGA. The parent compound was monitored at five time points over 90 min.

microsome (RLM) stability, PAMPA permeability, and aqueous solubility (pH 7.4). Both compounds exhibited high microsomal stabilities of >30 min (data not shown), the highest estimable  $T_{1/2}$  from a single measurement at 15 min.<sup>29</sup> Owing to the presence of a carboxylic acid moiety, PAMPA permeability was low ( $(1-8) \times 10^{-6}$  cm/s) while solubility was high (>82  $\mu\text{g}/\text{mL}$ , the maximum concentration tested in the assay). Time-course studies revealed that compounds were also stable in mouse and human liver microsomes ( $T_{1/2} > 200$  min for both compounds and species) and hepatocytes (mouse,  $T_{1/2} \approx 240$  min) (**Table 7**). Given the presence of both carboxylic acid and sulfonamide moieties in the lead molecules, the potential to form glucuronide conjugates exists. As such, we tested microsomal stability in the presence of NADPH/UDPGA substrates. Encouragingly, neither **61** nor **63** showed any evidence of glucuronidation when incubated in either mouse or human liver microsomes, suggesting phase II metabolism may not be a significant issue for this chemotype (data not shown). This observation was further supported by the long half-life in mouse hepatocytes.

As a result of the encouraging ADME data of lead compounds, the *in vivo* PK properties of lead compounds were determined. Both compounds showed clearance values that far exceed hepatic blood flow (HBF) in mouse species ( $90 \text{ mL min}^{-1} \text{ kg}^{-1}$ ), with *in vivo* clearances of 294 and 227  $\text{mL min}^{-1} \text{ kg}^{-1}$  for **61** and **63**, respectively (**Table 8**). These data, coupled with the long half-life in mouse liver microsomes, suggested a mechanism other than liver metabolism was contributing significantly to compound elimination *in vivo*. Potential explanations for clearance much greater than hepatic blood flow include compound instability in plasma, renal clearance, sequestration in erythrocytes, and/or high volume of

**Table 8. Pharmacokinetic Profiles of 61 and 63 in CD1 Mice<sup>a</sup>**

parameter	<b>61</b>		<b>63</b>	
	iv	po	iv	po
Cl ( $\text{L h}^{-1} \text{ kg}^{-1}$ )	227		294	
$T_{1/2}$ (h)	0.85	1.94	2.98	3.75
$C_{\max}$ ( $\mu\text{M}$ )	1.45 <sup>b</sup>	1.20	0.74 <sup>b</sup>	1.78
$T_{\max}$ (h)		0.25		0.25
$AUC_{\text{last}}$ ( $\mu\text{M}\cdot\text{h}$ )	0.26	3.2	0.19	2.5
$V_{\text{ss}}$ ( $\text{L/kg}$ )	5.6		27	
$F$ (%)		49		50

<sup>a</sup>Values calculated from drug concentration in plasma following iv (2  $\text{mg/kg}$ ) and po (50  $\text{mg/kg}$ ) dosing.  $n = 3$ , 8 time points taken over 24 h. Compounds **61** and **63** were formulated as solution in PBS buffered saline with 1.1 equiv of NaOH (final pH 7–8). <sup>b</sup> $C_{\max} = C_0 (t = 0)$  for IV administration. All pharmacokinetic studies were conducted at Pharmaron Inc.

distribution. These compounds were demonstrably stable in mouse plasma, with no degradation observed over 120 min (**Table 7**). Notably, compound **63** did exhibit a high volume of distribution, possibly accounting for some of the observed high clearance values. However, further studies are required to determine whether renal clearance or erythrocyte sequestration is a contributing factor, and ongoing medicinal chemistry optimization around this chemotype may lead to compounds with improved PK properties for use in animal studies. Encouragingly, despite their high clearance and poor PAMPA permeability, appreciable systemic exposure was achieved in the range of cellular  $IC_{50}$  values following po dosing at 50  $\text{mg/kg}$ . Passive absorption was undoubtedly impacted by the presence of a carboxylic acid moiety, yet bioavailability ( $F$ ) was determined to be ~50% for both compounds, suggesting that analogs with reduced clearance may lead to satisfactory exposure following oral dosing. Given the SAR for this series, which demonstrated the critical importance of the carboxylic acid moiety, future efforts to improve PK properties will focus on other areas of the molecule.

## CONCLUSION

LDH has long been implicated in the pathogenesis of cancer and many other diseases and thus has received considerable attention from both pharmaceutical companies and the academic scientific community. Despite multiple efforts to discover potent and drug-like inhibitors of LDHA, few viable inhibitors emerged until the recent pioneering work by GSK and Genentech. These published inhibitors possess potent biochemical activity, yet their cellular effects remain modest and pronounced *in vivo* activity remains elusive. Herein, we describe the discovery and medicinal chemistry optimization of a potent and cell-active pyrazole-based inhibitor of LDH. The original “hit” molecule **5** was identified via a qHTS campaign, and medicinal chemistry optimization was aided by both crystallography efforts and a battery of biological assays. As noted by other groups, despite obtaining potent biochemical inhibition of LDH, early representatives in this series had very modest cellular activity (e.g., inhibition of lactate production). However, through utilization of target engagement assays (CETSA) and biophysical characterization (SPR), we gained insight into the drivers of cellular potency, with the target residency times of these analogs being a key determinant. To that end, we identified compound **63** as a chemical probe for

LDH and a promising lead compound worthy of further optimization, given its sub- $\mu\text{M}$  inhibition of lactate production, robust cellular target engagement, inhibition of glycolytic flux, and favorable off-rate in SPR studies. While **63** possesses some favorable ADME attributes (e.g., microsomal stability, solubility), additional optimization will be required to achieve a PK profile suitable for use in *in vivo* efficacy studies. Current efforts are focused on implementing the lessons learned so far, and outlined herein, to guide development of compounds with better cellular potency and PK properties. Results from these additional efforts, along with further biological characterization of the compounds, will be reported in due course.

## EXPERIMENTAL SECTION

**General Methods for Chemistry.** All air or moisture sensitive reactions were performed under positive pressure of nitrogen or argon with oven-dried glassware. Anhydrous solvents and bases such as dichloromethane, *N,N*-dimethylformamide (DMF), acetonitrile, ethanol, DMSO, dioxane Hunig's base, and triethylamine were purchased from Sigma-Aldrich. Palladium catalysts were purchased from Strem Chemicals and used as such. SiliaCat heterogeneous catalyst DPP-Pd (catalog no. R390-100) was purchased from SiliCycle Inc. Preparative purification was performed on a Waters semipreparative HPLC system using a Phenomenex Luna C18 column ( $5 \mu\text{m}$ ,  $30 \text{ mm} \times 75 \text{ mm}$ ) at a flow rate of  $45 \text{ mL/min}$ . The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10–50% acetonitrile over 8 min was used during the purification. Fraction collection was triggered by UV detection (220 nm). Analytical analysis was performed on an Agilent LC/MS (Agilent Technologies, Santa Clara, CA). Method 1: A 7 min gradient of 4–100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8 min run time at a flow rate of  $1 \text{ mL/min}$ . A Phenomenex Luna C18 column ( $3 \mu\text{m}$ ,  $3 \text{ mm} \times 75 \text{ mm}$ ) was used at a temperature of  $50^\circ\text{C}$ . Method 2: A 3 min gradient of 4–100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with a 4.5 min run time at a flow rate of  $1 \text{ mL/min}$ . A Phenomenex Gemini Phenyl column ( $3 \mu\text{m}$ ,  $3 \text{ mm} \times 100 \text{ mm}$ ) was used at a temperature of  $50^\circ\text{C}$ . Purity determination was performed using an Agilent diode array detector for both method 1 and method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode.  $^1\text{H}$  NMR spectra were recorded on Varian 400 MHz spectrometers. Chemical shifts are reported in ppm with undeuterated solvent ( $\text{DMSO}-d_6$  at 2.49 ppm) as internal standard for  $\text{DMSO}-d_6$  solutions. All of the analogs tested in the biological assays have purity greater than 95%, based on both analytical methods. High resolution mass spectrometry was recorded on Agilent 6210 time-of-flight LC/MS system. Confirmation of molecular formula was accomplished using electrospray ionization in the positive mode with the Agilent Masshunter software (version B.02).

**General Procedure for the Synthesis of Acylbenzotriazole Derivatives (Method A).** To a solution of *1H*-benzo[*d*][1,2,3]-triazole (23.8 g, 200 mmol, 4 equiv) in  $\text{CH}_2\text{Cl}_2$  (150 mL) was added thionyl chloride (3.65 mL, 49.9 mmol, 1 equiv), and the mixture was stirred at room temperature for 0.5 h. Appropriate alkylcarboxylic acid (49.9 mmol, 1 equiv) was then added slowly, and the mixture was stirred for another 2 h. The reaction mixture was filtered, and the filter cake was washed with  $\text{CH}_2\text{Cl}_2$  (50 mL). The filtrate was neutralized with bicarbonate solution slowly and stirred for 30 min and then transferred to a separatory funnel. The organic layer was washed with bicarbonate solution and then with brine, dried over  $\text{MgSO}_4$ , filtered, and concentrated. The residue was purified directly on a flash system using 120 g silica column eluting with 0–20% ethyl acetate in hexanes over 15 column volumes. The first peak was collected and dried to get an oil or solid.

**General Procedure for the Synthesis of 1-Aryl-3-substituted Propane-1,3-diones (Method B).** To a mixture of acetophenone

**59a** or **61a** (51.0 mmol, 1 equiv), magnesium bromide diethyl etherate (32.9 g, 127 mmol, 2.5 equiv), and acylbenzotriazole derivative **58a** or **62a** (76 mmol, 1.5 equiv in  $\text{CH}_2\text{Cl}_2$  (100 mL)) was added Hunig's base (26.7 mL, 153 mmol, 3 equiv) slowly (cooling is necessary for large scale), and then the mixture was stirred at rt for 12 h. The reaction mixture was cooled in an ice bath and quenched with 1 M HCl. The product was extracted with  $\text{CH}_2\text{Cl}_2$ , and the organic layer was subsequently washed with brine. After drying the organic layer with  $\text{MgSO}_4$ , the crude product was purified on a ISCO flash system using a 220 g gold column, eluting with 0–30% ethyl acetate over 20 column volumes in hexanes to afford a yellow oil after removing the solvent in 60–69% yield.

**General Procedure for the Alkylation of 1-Aryl-3-Substituted Propane-1,3-diones (Method C).** 1-Aryl-3-substituted propane-1,3-dione (35.9 mmol, 1 equiv) and cesium carbonate (14.05 g, 43.1 mmol, 1.2 equiv) in DMSO (25 mL) were stirred at room temperature for 10 min. 4-(Bromomethyl)benzenesulfonamide (10.78 g, 43.1 mmol, 1.2 equiv) was added in one portion and further stirred at room temperature for another 1–2 h. The resulting mixture was diluted with large excess ethyl acetate and filtered through Celite to remove any solid impurities. The filtrate was washed with saturated ammonium chloride 3 times and then with brine. The organic layer was dried with  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated under reduced pressure. The residue was purified directly on flash system using a 220 g silica column, eluting with 20–60% ethyl acetate in hexanes over 16 column volumes to afford pure products **58c**, **61c**–**63c** in 55–83% yield.

**General Procedure for the Cyclization of 1-Aryl-2,3-disubstituted Propane-1,3-diones and Hydrolysis (Method D).** A mixture of appropriate 1-aryl-2, 3-disubstituted propane-1,3-dione (2.24 mmol, 1 equiv), ethyl 2-hydrazinylthiazole-4-carboxylate hydrogen bromide **III** (0.600 g, 2.24 mmol, 1 equiv), and tosic acid (0.425 g, 2.24 mmol, 1 equiv) in ethanol (10 mL) was heated in a microwave for 15 min at  $150^\circ\text{C}$ . The excess solvent was removed using forced air, and the residue was taken in dichloromethane. The crude suspension was then directly loaded to a 100 g silica column fitted to a flash system and eluted with 20–40% ethyl acetate in hexanes to get a mixture of regioisomers in 77–83% yield. This mixture of products was taken as such in a THF–methanol (2:1) mixture and treated with 1.5 M solution (5 equiv) of aqueous lithium hydroxide. The reaction mixture was stirred for 1 h, the solvent was removed and acidified with 1 M hydrochloric acid and then extracted with ethyl acetate. After evaporation of the organic layer, the crude material was taken in DMSO and the regioisomers were separated on a preparative HPLC. The desired isomer was eluted as a second peak.

**(1*H*-Benzol[*d*][1,2,3]triazol-1-yl)(cyclopropyl)methanone (58a).** This compound was prepared using Method A starting from cyclopropanecarboxylic acid in 100% yield. LC–MS retention time: (method 2) = 3.256 min,  $m/z$  ( $M + H$ )<sup>+</sup> = 188.

**1-Cyclopropyl-3-phenylpropane-1,3-dione (58b).** This compound was prepared using method B starting from **58a** and **59a** in 60% yield. LC–MS retention time: (method 2) = 3.52 min,  $m/z$  ( $M + H$ )<sup>+</sup> = 189.

**4-(2-Benzoyl-3-cyclopropyl-3-oxopropyl)benzenesulfonamide (58c).** This compound was prepared using method C starting from **58b** in 61% yield. LC–MS retention time: (method 2) = 3.32 min,  $m/z$  ( $M + H$ )<sup>+</sup> = 358.

**2-(5-Cyclopropyl-3-phenyl-4-(4-sulfamoylbenzyl)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic Acid (58).** This compound was prepared using general method D starting from **58c** and **III**. LC–MS retention time: (method 1) 4.905 min and (method 2) 3.323 min.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  13.17 (s, 1H), 8.29 (s, 1H), 7.72–7.67 (m, 2H), 7.52–7.46 (m, 2H), 7.42–7.32 (m, 3H), 7.30–7.23 (m, 4H), 4.12 (s, 2H), 2.23 (tt,  $J = 8.5, 5.6 \text{ Hz}$ , 1H), 1.00–0.91 (m, 2H), 0.68–0.60 (m, 2H); HRMS (ESI)  $m/z$  ( $M + H$ )<sup>+</sup> calcd for  $C_{23}\text{H}_{21}\text{N}_4\text{O}_4\text{S}$ ; 481.0999 found 481.0992.

**2-(5-Cyclopropyl-3-phenyl-4-(4-sulfamoylphenoxy)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic Acid (59).** This compound was prepared using general method D starting from **59c** and **III**. LC–MS retention time: (method 1) 5.119 min and (method 2) 3.257 min.  $^1\text{H}$

NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 13.16 (s, 1H), 8.35 (s, 1H), 7.83–7.71 (m, 4H), 7.45–7.31 (m, 3H), 7.29–7.14 (m, 4H), 2.63 (tt, *J* = 8.5, 5.5 Hz, 1H), 0.99–0.88 (m, 2H), 0.92–0.80 (m, 2H); HRMS (ESI) *m/z* (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub>O<sub>5</sub>S, 483.0791; found, 483.0809.

**2-(3-([1,1'-Biphenyl]-3-yl)-5-cyclopropyl-4-(4-sulfamoylphenoxy)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic Acid (60).** This compound was prepared using general method D starting from **60c** and **III**. LC–MS retention time: (method 1) 5.823 min and (method 2) 3.496 min. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 13.17 (s, 1H), 8.36 (s, 1H), 7.93 (td, *J* = 1.8, 0.5 Hz, 1H), 7.85–7.71 (m, 3H), 7.66 (ddd, *J* = 7.8, 1.9, 1.1 Hz, 1H), 7.56–7.32 (m, 6H), 7.30–7.21 (m, 4H), 2.73–2.61 (m, 1H), 1.02–0.90 (m, 2H), 0.93–0.83 (m, 2H); HRMS (ESI) *m/z* (M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>23</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub>, 559.1104; found, 559.1127.

**1-([1,1'-Biphenyl]-3-yl)-3-cyclopropylpropane-1,3-dione (61b).** This compound was prepared using method B starting from **58a** and **61a** in 66% yield. LC–MS retention time: (method 2) = 3.85 min, *m/z* (M + H)<sup>+</sup> = 265.

**4-(2-Benzoyl-3-cyclopropyl-3-oxopropyl)benzenesulfonamide (61c).** This compound was prepared using method C starting from **61b** in 63% yield. LC–MS retention time: (method 2) 3.46 min, *m/z* (M + H)<sup>+</sup> = 434.

**2-(3-([1,1'-Biphenyl]-3-yl)-5-cyclopropyl-4-(4-sulfamoylbenzyl)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic Acid (61).** This compound was prepared using general method D starting from **61c** and **III**. LC–MS retention time: (method 1) 5.636 min and (method 2) 3.556 min. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 13.09 (s, 1H), 8.31 (s, 1H), 7.78–7.72 (m, 2H), 7.67 (ddd, *J* = 7.5, 1.9, 1.3 Hz, 1H), 7.60 (td, *J* = 1.8, 0.6 Hz, 1H), 7.57–7.45 (m, 2H), 7.40 (d, *J* = 4.3 Hz, 4H), 7.36–7.30 (m, 3H), 7.28 (s, 2H), 4.17 (s, 2H), 2.28 (tt, *J* = 8.6, 5.6 Hz, 1H), 1.09–0.85 (m, 2H), 0.77–0.54 (m, 2H); HRMS (ESI) *m/z* (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub>S, 557.1312; found, 557.1320.

**1-(1*H*-Benzo[d][1,2,3]triazol-1-yl)-2-cyclopropylethan-1-one (62a).** This compound was prepared using method A from 2-cyclopropylacetic acid in 91% yield. LC–MS retention time: (method 2) 3.53 min, *m/z* (M + H)<sup>+</sup> = 202.

**4-Cyclopropyl-1-phenylbutane-1,3-dione (62b).** This compound was prepared using method B starting from **62a** and **59a** in 63% yield. LC–MS retention time: (method 2) = 3.76 min, *m/z* (M + H)<sup>+</sup> = 203.

**4-(2-Benzoyl-4-cyclopropyl-3-oxobutyl)benzenesulfonamide (62c).** This compound was prepared using method C starting from **62b** in 55% yield. LC–MS retention time: (method 2) = 3.35 min, *m/z* (M + H)<sup>+</sup> = 372.

**2-(5-Cyclopropylmethyl)-3-phenyl-4-(4-sulfamoylbenzyl)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic Acid (62).** This compound was prepared using general method D starting from **62c** and **III**. LC–MS retention time: (method 1) 5.199 min and (method 2) 3.495 min. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 13.15 (s, 1H), 8.29 (s, 1H), 7.74–7.66 (m, 2H), 7.60–7.53 (m, 2H), 7.44–7.36 (m, 3H), 7.32–7.25 (m, 4H), 4.14 (s, 2H), 3.15 (d, *J* = 6.9 Hz, 2H), 1.22–1.05 (m, 1H), 0.38–0.28 (m, 2H), 0.26–0.17 (m, 2H); HRMS (ESI) *m/z* (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub>S<sub>2</sub>, 495.1155; found, 495.1174.

**1-([1,1'-Biphenyl]-3-yl)-4-cyclopropylbutane-1,3-dione (63b).** This compound was prepared using method B starting from **62a** and **61a** in 69% yield. LC–MS retention time: (method 2) 4.02 min, *m/z* (M + H)<sup>+</sup> = 279.

**4-(2-([1,1'-Biphenyl]-3-carbonyl)-4-cyclopropyl-3-oxobutyl)benzenesulfonamide (63c).** This compound was prepared using method C starting from **63b** in 83% yield. LC–MS retention time: (method 2) 3.59 min, *m/z* (M + H)<sup>+</sup> = 448.

**2-(3-([1,1'-Biphenyl]-3-yl)-5-(cyclopropylmethyl)-4-(4-sulfamoylbenzyl)-1*H*-pyrazol-1-yl)thiazole-4-carboxylic Acid (63).** This compound was prepared using general method D starting from **63c** and **III**. LC–MS retention time: (method 1) 6.08 min and (method 2) 3.521 min. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 13.11 (s, 1H), 8.28 (s, 1H), 7.75–7.69 (m, 2H), 7.68–7.62 (m, 2H), 7.59 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.52–7.45 (m, 1H), 7.45–7.37 (m, 4H), 7.35–7.29 (m, 3H), 7.27 (s, 2H), 4.16 (s, 2H), 3.16 (d, *J* = 6.9 Hz, 2H), 1.20–1.03 (m, 1H), 0.37–0.28 (m, 2H), 0.24–0.18 (m, 2H); HRMS (ESI) *m/z* (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub>S, 571.1468; found, 571.1471.

**Cell Lines.** The MiaPaCa-2 and A673 cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were cultured in DMEM (Invitrogen 11965118) culture medium supplemented with 10% fetal bovine serum and 100 units/mL penicillin, 100 μg/mL streptomycin and maintained in a 37 °C, 5% CO<sub>2</sub>/95% humidified air incubator.

**Biochemical Assays.** **LDHA Biochemical Assay.** Briefly, 3 μL of human lactate dehydrogenase S (no. A38558H, Meridian Life Science, Inc., Memphis, TN) in LDH assay buffer (200 mM Tris HCl, pH 7.4, 100 μM EDTA, and 0.01% Tween-20) was added to a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintoool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of DMSO-solubilized compound (both library and vehicle controls) to each 1536-well assay plate. Following compound transfer, 1 μL of substrate solution containing NADH and sodium pyruvate (Sigma-Aldrich, St. Louis, MO) in LDH assay buffer was dispensed via BioRAPTR FRD to initiate the reaction. Final concentrations in the 4 μL reaction volume were 2 nM LDHA enzyme, 0.06 mM NADH, and 0.2 mM sodium pyruvate. Following a 5 min incubation period at room temperature, 1 μL of detection reagent (*C. kluyveri* diaphorase (Sigma-Aldrich) and resazurin sodium salt (Sigma-Aldrich) in LDH assay buffer) was added to a total volume of 5 μL. Final concentrations of detection reagents were 0.133 mg/mL diaphorase and 37 μM resazurin. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (ex 540 nm, em 590 nm) at 0 and 20 min. Fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate.

**LDHB Biochemical Assay.** Human lactate dehydrogenase 1 (no. A38155H, Meridian Life Science, Inc., Memphis, TN) was assayed as described above for LDHA. Final concentrations in the 4 μL reaction volume were 2 nM LDHB enzyme, 130 μM NADH, and 160 μM sodium pyruvate.

**MDH Biochemical Assay.** Briefly, 3 μL of MDH solution (containing 13.33 IU/mL malate dehydrogenase from porcine heart, 0.2 mM NAD, 0.067 mg/mL diaphorase, and 0.067 mM resazurin in MDH assay buffer (50 mM Tris, pH 8.0, 5 mM MgCl<sub>2</sub>, 0.01% Brij 3)) was added to a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintoool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of DMSO-solubilized compound (Cherrypick plates) to each 1536-well assay plate. Following compound transfer, plates were incubated at room temperature for 10 min. 1 μL of substrate solution containing malic acid (160 μM) was dispensed via BioRAPTR FRD to initiate the reaction. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (ex 540 nm, em 590 nm) at 0 and 5 min. Well fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate, and changes in fluorescence (ΔRFU) were calculated using the difference in fluorescent signal for each well at 5 versus 0 min.

**IDH1 Biochemical Assay.** IDH1 protocol was performed as previously described.<sup>30</sup> WT IDH1 (3 μL) in assay buffer (20 mM Tris, pH 7.5, 10 mM MgCl<sub>2</sub>, 150 mM NaCl, and 0.05% protease-free BSA) was added to the black solid bottom 1536-well assay plate using a BioRAPTR flying reagent dispenser (BioRAPTR; Beckman Coulter). A pintoool (Kalypsys) was used to transfer 23 nL of compound solution (library and control) to the 1536-well assay plates, and plates were spun down at 1000 rpm for 1 min. After 30 min of incubation at room temperature, 1 μL of substrate buffer was added to initiate the reaction at final concentrations of 0.045 μg/mL enzyme, 2 mM BME, 240 μM isocitrate, 180 μM NADP<sup>+</sup>, 60 μg/mL diaphorase, and 37.5 μM resazurin. The plate was rapidly transferred to a ViewLux (PerkinElmer), and the fluorescence product resorufin was measured (excitation = 525 nm, emission = 598 nm) in kinetic mode. The plates were read continuously from *t* = 0 to *t* = 5 min.

**Lactate Production Assays.** A673 and MiaPaCa-2 cells were cultured as described above and plated in 1536-well black clear bottom

tissue culture plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 500 cells/well in 4  $\mu$ L of DMEM (Invitrogen 31053036) culture medium. A 1536-well pintoool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of compound in DMSO to the 1536-well assay plates. After a 2 h incubation at 37 °C, 2  $\mu$ L of reconstituted lactate reaction mix (BioVision K607-100) was dispensed into each well using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). Plates were incubated at room temperature for 30 min, transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and the fluorescence (Ex/Em 525/598 nm) and absorbance (573 nm) were measured accordingly.

**Cellular Thermal Shift Assay (CETSA).** The cellular thermal shift assay and the isothermal dose response were run as previously described.<sup>27</sup> Additional details are described in [supplemental methods](#).

**Cytotoxicity Assay.** A673 and MiaPaCa-2 cells were cultured as described above and plated in 1536-well white solid tissue culture plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 500 cells/well in 5  $\mu$ L of DMEM (Invitrogen 11965118) culture medium supplemented with 10% fetal bovine serum and 100 units/mL penicillin, 100  $\mu$ g/mL streptomycin. A 1536-well pintoool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of compound in DMSO to the 1536-well assay plates. After a 48 h incubation at 37 °C, 2.5  $\mu$ L of CellTiter-Glo (Promega) was dispensed into each well using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). Plates were incubated at room temperature for 10 min, transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and the ATP-coupled luminescence was measured using a 1 s exposure.

**Incucyte Long-Term Growth Inhibition Assay.** A673 and MiaPaCa-2 cells were cultured as described above and plated in 384-well black clear bottom tissue culture plates using an multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 1000 cells/well in 40  $\mu$ L of DMEM (11965118) culture medium supplemented with 10% fetal bovine serum and 100 units/mL penicillin, 100  $\mu$ g/mL streptomycin. DMSO-solubilized compounds were added using a 384-well pintoool dispenser (Wako Automation, San Diego, CA), and plates were incubated and measured in an IncuCyte ZOOM live cell analysis system (Essen Bioscience, Ann Arbor, MI) in a cell culture environment at 37 °C containing 5% CO<sub>2</sub>. Cell confluence was assessed using high definition phase contrast every 4 h for a total of 120 h. Area under the curve and dose-response curve analyses was performed using Prism (GraphPad Software).

**Glycolytic Stress Test Assay.** A673 cells were cultured in Dulbecco's modified Eagle's medium (ATCC catalog no. 302002) supplemented with fetal bovine serum (10%). The cells were plated into a XF96 cell culture microplate in the above medium and maintained in a 5% CO<sub>2</sub> incubator at 37 °C for 24 h prior to the experiments. The day of the assay, compounds are diluted to the appropriate concentration in freshly prepared assay medium (Seahorse basic DMEM with 2 mM glutamine, pH 7.4 at 37 °C). The medium in the plate with cells was then changed to assay medium and maintained in a non-CO<sub>2</sub> incubator at 37 °C for 1 h prior to the assay. The Seahorse XF glycolysis stress test (GST) was conducted by injecting the LDH inhibitors and then, at 40 min, subsequent injections of glucose (10 mM final concentration), oligomycin (1  $\mu$ g/mL final concentration), and 2-deoxyglucose (2-DG; 50 mM final concentration) as described in ref 31.

**PAMPA Permeability Assay.** The stirring double-sink PAMPA method patented by PION Inc. (Billerica, MA) was employed to determine the permeability of compounds via PAMPA passive diffusion. The PAMPA lipid membrane consisted of an artificial membrane of a proprietary lipid mixture and dodecane (Pion Inc.), optimized to predict gastrointestinal tract (GIT) passive diffusion permeability, and was immobilized on a plastic matrix of a 96-well "donor" filter plate placed above a 96 well "acceptor" plate. A pH 7.4 solution was used in both donor and acceptor wells. The test articles, stocked in 10 mM DMSO solutions, were diluted to 0.05 mM in aqueous buffer (pH 7.4), and the concentration of DMSO was 0.5% in the final solution. During the 30 min permeation period at room

temperature, the test samples in the donor compartment were stirred using the Gutbox technology (Pion Inc.) to reduce the unstirred water layer. The test article concentrations in the donor and acceptor compartments were measured using an UV plate reader (Nano Quant, Infinite 200 PRO, Tecan Inc., Männedorf, Switzerland). Permeability calculations were performed using Pion Inc. software and were expressed in units of 10<sup>-6</sup> cm/s.

**Kinetic Solubility Test Assay.** Pion's patented  $\mu$ SOL assay for kinetic solubility determination was used. In this assay, the classical saturation shake-flask solubility method was adapted to a 96-well microtiter plate format and a cosolvent method with *n*-propanol as the reference compound was utilized. Test compounds were prepared in 10 mM DMSO solutions (45  $\mu$ L) and diluted with the cosolvent to a final drug concentration of 150  $\mu$ M in the aqueous solution (pH 7.4). Samples are incubated at room temperature for 6 h to achieve equilibrium. The samples were then filtered to remove any precipitate formed. The concentration of the compound in the filtrate was measured by UV absorbance. The reference drug concentration of 17  $\mu$ M was used for quantitation of unknown drug concentration in filtrate. Spectroscopically pure 1-propanol was used as a cosolvent to suppress precipitation in the reference solutions. The kinetic solubility ( $\mu$ g/mL) was calculated with using the  $\mu$ SOL Evolution software.

**Rat Liver Microsome Stability Assay.** See ref 30 for details.

**Mouse Pharmacokinetic Studies.** Studies were conducted by Pharmaron. Male CD1 mice (sourced from Si Bei Fu Laboratory Animal Technology Co. Ltd.), approximately 6–8 weeks of age and a weight of approximately 20–30 g, were dosed with 61 and 63 at 2 mg/kg (iv) and 50 mg/kg (po). The formulation (0.1 M NaOH in PBS buffered saline, adjusted with 1 N HCl to pH 7–8.5) was prepared on the day of dosing or directly prior to dosing. Each cohort had three mice, and plasma was collected at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h postdose for iv and 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h for po. Approximately 0.025 mL of blood was collected via the dorsal metatarsal vein at each time point. Blood samples were then transferred into plastic microcentrifuge tubes containing heparin-Na as anticoagulant. Samples were then centrifuged at 4000g for 5 min at 4 °C to obtain plasma. Plasma samples were then stored in polypropylene tubes, quickly frozen, and kept at –75 °C until analyzed by LC/MS/MS. The following pharmacokinetic parameters were measured:  $T_{1/2}$ ,  $C_0$ ,  $C_{max}$ ,  $T_{max}$ , CL,  $V_d$ , AUC<sub>last</sub>, and *F*. Animals were also monitored during the in-life phase by once daily cageside observations; any adverse clinical signs are noted as part of the PK report.

**Use of Animal Subjects.** All animal studies included as part of this manuscript were performed in accordance with institutional guidelines as defined by Institutional Animal Care and Use Committee (IACUC).

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.jmedchem.7b00941](https://doi.org/10.1021/acs.jmedchem.7b00941).

Additional figures, experimental procedures, and spectroscopic data (<sup>1</sup>H NMR, LC/MS, and HRMS) for representative compounds ([PDF](#))

Molecular formula strings and some data ([CSV](#))

### Accession Codes

Protein Data Bank codes are the following: 5W8I (27), 5W8H (15), 5W8J (33), 5W8K (33), 5W8L (63). Authors will release the atomic coordinates and experimental data upon article publication.

## AUTHOR INFORMATION

### Corresponding Authors

\*G.R.: phone, 301-217-0263; fax, 301-217-5736; e-mail, [bantukallug@mail.nih.gov](mailto:bantukallug@mail.nih.gov).

\*D.J.M.: phone, 301-857-1899; e-mail, [dmaloneyn@inspyrxtx.com](mailto:dmaloneyn@inspyrxtx.com).

#### ORCID

Matthew D. Hall: [0000-0002-5073-442X](https://orcid.org/0000-0002-5073-442X)

David J. Maloney: [0000-0002-5607-4178](https://orcid.org/0000-0002-5607-4178)

#### Present Addresses

<sup>○</sup>D.J.M.: Inspyr Therapeutics, 31200 Via Colinas, Suite 200, Westlake Village, CA 91362.

<sup>◆</sup>E.J.K.: Department of Chemistry, University of California, Irvine, CA 92697.

<sup>¶</sup>C.M.L.: Moderna, 500 Technology Square, Cambridge, MA, 02139.

#### Author Contributions

<sup>∞</sup>G.R. and K.R.B. contributed equally to this work.

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. G.R., K.R.B., B.T.M., D.J.M., X.H., S.-M.Y., T.D.L., D.M.C., J.K., K.P., E.J.K., D.K.L., H.Z., M.D.H., A.S., A.J., and D.J.M. also gratefully acknowledge funding by the Intramural Research Program, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH). The authors thank Sam Michael and Richard Jones for automation support; Paul Shinn, Misha Itkin, Zina Itkin, and Danielle van Leer for the assistance with compound management; William Leister, Heather Baker, Elizabeth Fernandez, and Christopher Leclair for analytical chemistry and purification support; Kimloan Nguyen for in vitro ADME data. We also thank Genentech for the generous donation of GNE140 for our studies, David Myszka at Biosenor Tools for conducting the SPR experiments, and Pharmaron Inc. for conducting the pharmacokinetic studies.

#### ABBREVIATIONS USED

LDH, lactate dehydrogenase; qHTS, quantitative high-throughput screening; CETSA, cellular thermal shift assay; SPR, surface plasmon resonance; SAR, structure-activity relationship; TFA, trifluoroacetic acid; LHMDs, lithium bis(trimethylsilyl)amide; HATU, 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxide hexafluorophosphate; MW, microwave; TBAF, tetra-*n*-butylammonium fluoride; NCGC, NIH Chemical Genomics Center; EDTA, ethylenediaminetetraacetic acid

#### REFERENCES

- (1) Warburg, O.; Posener, K.; Negelein, E. Ueber den stoffwechsel der tumoren. *Biochem. Z.* **1924**, *152*, 319–344.
- (2) Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* **2009**, *324*, 1029–1033.
- (3) Yu, Y.; Liao, M.; Liu, R.; Chen, J.; Feng, H.; Fu, Z. Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment. *World J. Surg. Oncol.* **2014**, *12*, 78.

(4) Rong, Y.; Wu, W.; Ni, X.; Kuang, T.; Jin, D.; Wang, D.; Lou, W. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. *Tumor Biol.* **2013**, *34*, 1523–1530.

(5) (a) Fantin, V. R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* **2006**, *9*, 425–434. (b) Le, A.; Cooper, C. R.; Gouw, A. M.; Dinavahi, R.; Maitra, A.; Deck, L. M.; Royer, R. E.; Vander Jagt, D. L.; Semenza, G. L.; Dang, C. V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 2037–2042. (c) Sheng, S. L.; Liu, J. J.; Dai, Y. H.; Sun, X. G.; Xiong, X. P.; Huang, G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. *FEBS J.* **2012**, *279*, 3898–3910. (d) Wang, Z. Y.; Loo, T. Y.; Shen, J. G.; Wang, N.; Wang, D. M.; Yang, D. P.; Mo, S. L.; Guan, X. Y.; Chen, J. P. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. *Breast Cancer Res. Treat.* **2012**, *131*, 791–800. (e) Yao, F.; Zhao, T.; Zhong, C.; Zhu, J.; Zhao, H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. *Tumor Biol.* **2013**, *34*, 25–31.

(6) (a) Giatromanolaki, A.; Sivridis, E.; Gatter, K. C.; Turley, H.; Harris, A. L.; Koukourakis, M. I. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. *Gynecol. Oncol.* **2006**, *103*, 912–918. (b) Koley, Y.; Utetake, H.; Takagi, Y.; Sugihara, K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. *Ann. Surg. Oncol.* **2008**, *15*, 2336–2344. (c) Koukourakis, M. I.; Giatromanolaki, A.; Sivridis, E.; Bougioukas, G.; Didilis, V.; Gatter, K. C.; Harris, A. L. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. *Br. J. Cancer* **2003**, *89*, 877–885.

(7) Daniele, S.; Giacomelli, C.; Zappelli, E.; Granchi, C.; Trincavelli, M. L.; Minutolo, F.; Martini, C. Lactate dehydrogenase-A inhibition induced human glioblastoma multiforme stem cell differentiation and death. *Sci. Rep.* **2015**, *5*, 15556.

(8) Blum, R.; Kloog, Y. Metabolism addition in pancreatic cancer. *Cell Death Dis.* **2014**, *5*, e1065.

(9) Shuch, B.; Linehan, M. W.; Srinivasan, R. Aerobic glycolysis: A novel target in kidney cancer. *Expert Rev. Anticancer Ther.* **2013**, *13*, 711–719.

(10) Granchi, C.; Roy, S.; Giacomelli, C.; Macchia, M.; Tuccinardi, T.; Martinelli, A.; Lanza, A.; Betti, L.; Giannaccini, G.; Lucacchini, A.; Funel, N.; León, L. G.; Giovannetti, E.; Peters, G. J.; Palchaudhuri, R.; Calvaresi, E. C.; Hergenrother, P. J.; Minutolo, F. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents againsts cancer cells. *J. Med. Chem.* **2011**, *54*, 1599–1612.

(11) Kohlmann, A.; Zech, S. G.; Li, F.; Zhou, T.; Squillace, R. M.; Commodore, L.; Greenfield, M. T.; Lu, X.; Miller, D. P.; Huang, W.-S.; Qi, G.; Thomas, R. M.; Wang, Y.; Zhang, S.; Dodd, R.; Liu, S.; Xu, R.; Xu, Y.; Miret, J. J.; Rivera, V.; Clackson, T.; Shakespeare, W. C.; Zhu, X.; Dalgarno, D. C. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. *J. Med. Chem.* **2013**, *56*, 1023–1040.

(12) Ward, R. A.; Brassington, C.; Breeze, A. L.; Caputo, A.; Critchlow, S.; Davies, G.; Goodwin, L.; Hassall, G.; Greenwood, R.; Holdgate, G. A.; Mrosek, M.; Norman, R. A.; Pearson, S.; Tart, J.; Tucker, J. A.; Vogtherr, M.; Whittaker, D.; Wingfield, J.; Winter, J.; Hudson, K. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. *J. Med. Chem.* **2012**, *55*, 3285–3306.

(13) Billiard, J.; Dennison, J. B.; Briand, J.; Annan, R. S.; Chai, D.; Colón, M.; Dodson, C. S.; Gilbert, S. A.; Greshock, J.; Jing, J.; Lu, H.; McSurdy-Freed, J. E.; Orband-Miller, L. A.; Mills, G. B.; Quinn, C. J.; Schneck, J. L.; Scott, G. F.; Shaw, A. N.; Waitt, G. M.; Wooster, R. F.;

- Duffy, K. J. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. *Cancer Metab.* **2013**, *1*, 19.
- (14) (a) Fauber, B. P.; Dragovich, P. S.; Chen, J.; Corson, L. B.; Ding, C. Z.; Eigenbrot, C.; Giannetti, A. M.; Hunsaker, T.; Labadie, S.; Liu, Y.; Liu, Y.; Malek, S.; Peterson, D.; Pitts, K.; Sideris, S.; Ultsch, M.; VanderPorten, E.; Wang, J.; Wei, B.-Q.; Yen, I.; Yue, Q. Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 5533–5539. (b) Dragovich, P. S.; Fauber, B. P.; Corson, L. B.; Ding, C. Z.; Eigenbrot, C.; Ge, H.; Giannetti, A. M.; Hunsaker, T.; Labadie, S.; Liu, Y.; Malek, S.; Pan, B.; Peterson, D.; Pitts, K.; Purkey, H. E.; Sideris, S.; Ultsch, M.; VanderPorten, E.; Wei, B.; Xu, Q.; Yen, I.; Yue, Q.; Zhang, H.; Zhang, Z. Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 3186–3194. (c) Boudreau, A.; Purkey, H. E.; Hitz, A.; Robarge, K.; Peterson, D.; Labadie, S.; Kwong, M.; Hong, R.; Gao, M.; Del Nagro, C.; Pusapati, R.; Ma, S.; Salphati, L.; Pang, P.; Zhou, A.; Lai, T.; Li, Y.; Chen, Z.; Wei, B.; Yen, I.; Sideris, S.; McCleland, M.; Firestein, R.; Corson, L.; Vanderbilt, A.; Williams, S.; Daemen, A.; Belvin, M.; Eigenbrot, C.; Jackson, P. K.; Malek, S.; Hatzivassiliou, G.; Sampath, D.; Evangelista, M.; O'Brien, T. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. *Nat. Chem. Biol.* **2016**, *12*, 779–786.
- (15) Aggarwal, R.; Kumar, R.; Kumar, S.; Garg, G.; Mahajan, R.; Sharma, J. Synthesis and antibacterial activity of some 5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-thiocarboxamides, 3-trifluoromethylpyrazol-1-thiocarboxamides and 4-aryl-2-(5(3)-trifluoromethyl-1-pyrazolyl)thiazoles. *J. Fluorine Chem.* **2011**, *132*, 965–972.
- (16) (a) Denisova, A. B.; Glukhareva, T. V.; Andronnikova, G. P.; Mokrushin, V. S.; Dehaen, W.; Luyten, I.; Sosnovskikh, V. Y.; Van Meervelt, L.; Bakulev, V. A. Regioselectivity of the Synthesis of 2-pyrazolinylthiazoles by reacting 2-hydrazinothiazoles with unsymmetrical β-diketones. *J. Chem. Res., Miniprint* **2001**, *2001*, 12–13; *J. Chem. Res.*, **Miniprint** **2001**, 133–147. (b) Singh, S. P.; Kumar, D.; Batra, H.; Naithani, R.; Rozas, I.; Elguero, J. The reaction between hydrazines and b-dicarbonyl compounds: proposal for a mechanism. *Can. J. Chem.* **2000**, *78*, 1109–1120. (c) Denisova, A. B.; Sosnovskikh, V. Y.; Dehaen, W.; Toppet, S.; Van Meervelt, L.; Bakulev, V. A. The regioselectivity of the formation of 2-pyrazolinylthiazoles and their precursors from the reaction of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones. *J. Fluorine Chem.* **2002**, *115*, 183–192.
- (17) (a) Hornback, J. M.; Poundstone, M. L.; Vadlamani, B.; Graham, S. M.; Gabay, J.; Patton, S. T. Photochemical cyclization of o-methylphenyl 1,3-diketones. *J. Org. Chem.* **1988**, *53*, 5597–5601. (b) Wasserman, H. H.; Ennis, D. S.; Vu, C. B.; Schulte, G.; Munk, M. E.; Madison, M.; Velusamy, K. V. Synthesis and characterization of pyrroplinonecarboxylates formed by reaction of vicinal tricarbonyl derivatives with aldehyde schiff bases. *Heterocycles* **1993**, *35*, 975–995. (c) Hu, X.; Sun, J.; Wang, H.-G.; Manetsch, R. Bcl-XL-templated assembly of its own protein–protein interaction modulator from fragments decorated with thio acids and sulfonyl azides. *J. Am. Chem. Soc.* **2008**, *130*, 13820–13821.
- (18) Morimoto, H.; Tsubogo, T.; Litvinas, N. D.; Hartwig, J. F. A broadly applicable copper reagent for trifluoromethylations and perfluoroalkylations of aryl iodides and bromides. *Angew. Chem., Int. Ed.* **2011**, *50*, 3793–3798.
- (19) Inglese, J.; Auld, D. S.; Jadhav, A.; Johnson, R. L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C. P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proc. Natl. Acad. Sci. U. S. A.* **2006**, *103*, 11473–11478.
- (20) Atobe, M.; Naganuma, K.; Kawanishi, M.; Morimoto, A.; Kasahara, K.; Ohashi, S.; Suzuki, H.; Hayashi, T.; Miyoshi, S. Hit-to-lead optimization of 2-(1*H*-pyrazol-1-yl)-thiazole derivatives as a novel class of EP<sub>1</sub> receptor antagonist. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 6064–6067.
- (21) (a) Morpeth, F. F.; Massey, V. Metal binding to D-lactate dehydrogenase. *Biochemistry* **1982**, *21*, 1318–1323. (b) Marti, H. H.; Jung, H. H.; Pfilschifter, J.; Bauer, C. Hypoxia and cobalt stimulate lactate dehydrogenase (LDH) activity in vascular smooth muscle cells. *Pfluegers Arch.* **1994**, *429*, 216–222. (c) Cremona, T. The lactic dehydrogenase of yeast. *J. Biol. Chem.* **1963**, *239*, 1457–1465.
- (22) (a) Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug–Target residence time and its implication for lead optimization. *Nat. Rev. Drug Discovery* **2006**, *5*, 730–739. (b) Copeland, R. A. The drug–target residence time model: a 10-year retrospective. *Nat. Rev. Drug Discovery* **2016**, *15*, 87–95.
- (23) Berezov, A.; Zhang, H.-T.; Greene, M. I.; Murali, R. Disabling Erb B receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis. *J. Med. Chem.* **2001**, *44*, 2565–2574.
- (24) Itzhak, D. N.; Tyanova, S.; Cox, J.; Borner, G. H. Global, quantitative and dynamic mapping of protein subcellular localization. *eLife* **2016**, *5*, e16950.
- (25) GNE140 had not yet been disclosed when these studies were initially conducted.
- (26) (a) Chang, A.; Schiebel, J.; Yu, W.; Bommineni, G. R.; Pan, P.; Baxter, M. V.; Khanna, A.; Sottriffer, C. A.; Kisker, C.; Tonge, P. J. Rational optimization of drug-target residence time: Insights from inhibitor binding to the *S. aureus* FabI enzyme-product complex. *Biochemistry* **2013**, *52*, 4217–4228. (b) Cusack, K. P.; Wang, Y.; Hoemann, M. Z.; Marjanovic, J.; Heym, R. G.; Vasudevan, A. Design strategies to address kinetics of drug binding and residence time. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 2019–2027.
- (27) (a) Copeland, R. A. Conformational adaptation in drug-target interactions and residence time. *Future Med. Chem.* **2011**, *3*, 1491–1501. (b) Van Aller, G. S.; Pappalardi, M. B.; Ott, H. M.; Diaz, E.; Brandt, M.; Schwartz, B. J.; Miller, W. H.; Dhanak, D.; McCabe, M. T.; Verma, S. K.; Creasy, C. L.; Tummino, P. J.; Kruger, R. G. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. *ACS Chem. Biol.* **2014**, *9*, 622–629.
- (28) (a) Molina, D. M.; Jafari, R.; Ignatushchenko, M.; Seki, T.; Larsson, E. A.; Dan, C.; Sreekumar, L.; Cao, Y.; Nordlund, P. Monitoring drug target engagement in cells and tissues Using the cellular thermal shift assay. *Science* **2013**, *341*, 84–87. (b) Jafari, R.; Almqvist, H.; Axelsson, H.; Ignatushchenko, M.; Lundbäck, T.; Nordlund, P.; Molina, D. M. The cellular thermal shift assay for evaluating drug target interactions in cells. *Nat. Protoc.* **2014**, *9*, 2100–2122.
- (29) Di, L.; Kerns, E. H.; Gao, N.; Li, S. Q.; Huang, Y.; Bourassa, J. L.; Huryn, D. M. Experimental design on single-time-point high-throughput microsomal stability assay. *J. Pharm. Sci.* **2004**, *93*, 1537–1544.
- (30) Davis, M. I.; Shen, M.; Simeonov, A.; Hall, M. D. Diaphorase coupling protocols for red-shifting dehydrogenase assays. *Assay Drug Dev. Technol.* **2016**, *14*, 207–212.
- (31) Hill, B. G.; Benavides, G. A.; Lancaster, J. R.; Ballinger, S.; Dell’Italia, L.; Zhang, J.; Darley-Usmar, V. M. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. *Biol. Chem.* **2012**, *393*, 1485–1512.